{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.13944"}, {"@name": "filename", "#text": "20130_arquivo4876_1.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "Atividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nCENTRO DE CI\u00caNCIAS BIOL\u00d3GICAS \nDEPARTAMENTO DE BIOQU\u00cdMICA \n\nMESTRADO EM BIOQU\u00cdMICA \n  \n \n\n \n \n \n \n \n \n \n \n\nATIVIDADE ANTITUMORAL E TOXICIDADE DE NANOC\u00c1PSULAS \n\nCONTENDO O \u00c1CIDO FUMARPROTOCETR\u00c1RICO ISOLADO DE \n\nCladonia verticillaris (L\u00cdQUEN) \n\n \n\n \n \n \n\n \n \n\nANA CATARINA SIMONETTI \n \n\n \n \n \n\n \n \n \n\n \n\n \n\n \n\nOrientadora: Profa. Dra. Nereide Stela Santos Magalh\u00e3es \n\nCo-Orientador: Prof. Dr. Eryvaldo S\u00f3crates Tabosa do Egito \n\n \n \n \n \n\nRecife-PE \n2004 \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nCENTRO DE CI\u00caNCIAS BIOL\u00d3GICAS \nDEPARTAMENTO DE BIOQU\u00cdMICA \n\nMESTRADO EM BIOQU\u00cdMICA \n \n\n \n\n \n \n \n \n\nATIVIDADE ANTITUMORAL E TOXICIDADE DE NANOC\u00c1PSULAS \n\nCONTENDO O \u00c1CIDO FUMARPROTOCETR\u00c1RICO ISOLADO DE \n\nCladonia verticillaris (L\u00cdQUEN) \n\n \n \n \n \n \n\nANA CATARINA SIMONETTI \n \n \n\n \nDisserta\u00e7\u00e3o apresentada ao Curso de \n\nMestrado em Bioqu\u00edmica, do Centro de \nCi\u00eancias Biol\u00f3gicas da Universidade \nFederal de Pernambuco (UFPE) como pr\u00e9-\nrequisito \u00e0 obten\u00e7\u00e3o do t\u00edtulo de Mestre em \nBioqu\u00edmica. \n\n \n \n \n\nOrientadora: Profa. Dra. Nereide Stela Santos Magalh\u00e3es \n\nCo-Orientador: Prof. Dr. Eryvaldo S\u00f3crates Tabosa do Egito \n\n \n\n \n \n \n \n \n \n\nRecife-PE \n2004 \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \nUNIVERSIDADE FEDERAL DE PERNAMBUCO \n\nCENTRO DE CI\u00caNCIAS BIOL\u00d3GICAS \nDEPARTAMENTO DE BIOQU\u00cdMICA \n\nMESTRADO EM BIOQU\u00cdMICA \n \n\n \n \n \n\n \n\nATIVIDADE ANTITUMORAL E TOXICIDADE DE NANOC\u00c1PSULAS \n\nCONTENDO O \u00c0CIDO FUMARPROTOCETR\u00c1RICO ISOLADO DE \n\nCladonia verticillaris (L\u00cdQUEN) \n\n \n\n \n\n \n \n\nProfa. Dra. Nereide Stela Santos Magalh\u00e3es (Presidente) \nDepartamento de Bioqu\u00edmica-UFPE \n\n \n \n\nProfa. Dra. Maria da Paz Carvalho da Silva  \nDepartamento de Bioqu\u00edmica-UFPE \n\n \n \n\nProf. Dr. Jos\u00e9 Luiz de Lima Filho \nDepartamento de Bioqu\u00edmica-UFPE \n\n \n \n\nProf. Dr. Eryvaldo S\u00f3crates Tabosa do Egito (Examinador Externo) \nUniversidade Federal do Rio Grande do Norte-UFRN \n\n \n \n\nAna Catarina Simonetti (mestranda) \nDepartamento de Bioqu\u00edmica-UFPE \n\n \n \n \n \n\n \n \n\nRecife-PE \n2004 \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n \n \n\nAo meu av\u00f4, In memorian, Elias de Oliveira Lima, dedico a minha determina\u00e7\u00e3o.  \n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \nAGRADECIMENTOS \n\n \n \n\n\u00c0 Deus, pela maravilhosa oportunidade de viver, aprender e crescer \n\ncotidianamente em um mundo repleto de imperfei\u00e7\u00f5es. \n\nAos meus pais como intermedi\u00e1rios da minha vinda ao mundo. \n\nAo meu saudoso av\u00f4, Elias de Oliveira Lima, que fez com que a minha vida \n\nseguisse um rumo s\u00f3lido. \n\n \u00c0 minha m\u00e3e de cria\u00e7\u00e3o, Josefa Vitalina da Silva, que dedicou todos os \n\nmomentos da sua preciosa vida para educar um algu\u00e9m, com muito amor e carinho, \n\nmesmo sabendo das in\u00fameras dificuldades que a vida lhe traria. Obrigada mainha. \n\nAo meu namorado, Lenilton J\u00fanior, por toda paci\u00eancia, compreens\u00e3o e \n\nresigna\u00e7\u00e3o diante das dif\u00edceis fases ocorrentes em nossas vidas. A minha gratid\u00e3o ser\u00e1 \n\neterna. \n\nAos professores do Mestrado em Bioqu\u00edmica pela dedica\u00e7\u00e3o na arte de \n\ntransmitir seus s\u00e1bios conhecimentos, em especial Prof. Dr. Luis Bezerra e Prof\u00aa. Dr\u00aa. \n\nMaria da Paz pelo carisma por minha pessoa. \n\n\u00c0 Profa. Dra. Nereide Stela Santos Magalh\u00e3es que me ofereceu a oportunidade \n\nde aprender e crescer profissionalmente, pois o seu exemplo de trabalho aliado \u00e0 \n\nhonestidade fez-me crer que ainda pode-se obter sucesso apoiando-se nos princ\u00edpios da \n\nmera verdade. \n\n Ao Prof. Dr. S\u00f3crates Tabosa do Egito, Universidade Federal do Rio Grande do \n\nNorte-UFRN, pela aten\u00e7\u00e3o e intensa contribui\u00e7\u00e3o na conclus\u00e3o desta disserta\u00e7\u00e3o; \n\n \u00c1 Dra. Noemia Pereira dos Santos, Departamento de Antibi\u00f3ticos-UFPE, pela \n\nsua disposi\u00e7\u00e3o em me ajudar na realiza\u00e7\u00e3o deste trabalho, pois seu m\u00e9rito \u00e9 \n\nindispens\u00e1vel. \n\nAo Prof. Dr. Nic\u00e1cio Henrique da Silva, Departamento de Bioqu\u00edmica-UFPE, \n\npelo seu apoio no oferecimento do \u00e1cido fumarprotocetr\u00e1rico e das instala\u00e7\u00f5es do seu \n\nlaborat\u00f3rio para realiza\u00e7\u00e3o de parte deste trabalho. \n\n\u00c0 Profa. Dra Eug\u00eania Cristina Gon\u00e7alves Pereira pela sua colabora\u00e7\u00e3o na  \n\nobten\u00e7\u00e3o dos produtos  liqu\u00eanicos. \n\n\u00c1 Profa. Dra. Silene Carneiro do Nascimento, Departamento de Antibi\u00f3ticos-\n\nUFPE, pelo aux\u00edlio na realiza\u00e7\u00e3o dos testes com c\u00e9lulas e animais.  \n\nAo Prof. Dr. Jos\u00e9 Luiz de Lima Filho, diretor do LIKA, por cederas instala\u00e7\u00f5es \n\npara realiza\u00e7\u00e3o deste trabalho. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nAo Prof. Dr. Nicodemos Teles P. Filho pelo aux\u00edlio na interpreta\u00e7\u00e3o dos laudos \n\nhistopatol\u00f3gicos descritos nesta disserta\u00e7\u00e3o. \n\nAos amigos do Curso de Mestrado, Jo\u00e3o Soares, Rosangela Vidal, Lilia Moura, \n\nRegina Ara\u00fajo, Neila Caroline, Michele Dalvina, Alexandre Lib\u00e2nio, Nerivan Barbosa \n\ne Ana Ac\u00e1cia, pelos momentos de companheirismo. \n\nAos alunos de inicia\u00e7\u00e3o cient\u00edfica, Milena Ferraz, Marcela Wanderley e \n\nLuciano Fran\u00e7a do Laborat\u00f3rio de Imunopatologia Keiso Asami-LIKA, agrade\u00e7o-lhes \n\nimensamente pelo cumprimento de suas atividades com consider\u00e1vel responsabilidade. \n\nAos meus amigos do Laborat\u00f3rio de Bioqu\u00edmica-LIKA e do grupo SLC: \n\nRosangela Vidal, Herc\u00edlia Rolim, Roseane Ribeiro, Nerivan Barbosa, L\u00facio Pimentel, \n\nSimone Santos, Marcela Wanderley, Milena Ferraz, Mariane Lira, Marc\u00edlia Pinheiro, \n\nNoemia Santos, Dayse Vasconcelos, Jo\u00e3o Paulo, Agenor Tavares, Luciana da Matta, \n\nIan Porto, Lilia Moura, Jo\u00e3o Soares, Givanildo e Luciana Oliveira, pela amizade. \n\n\u00c0 Rosangela Vidal, Herc\u00edlia Rolim e Luciana da Matta pelos marcantes \n\nmomentos de companheirismo e amizade verdadeiros. \n\n\u00c1 Ian Porto pelo aux\u00edlio na descri\u00e7\u00e3o dos resultados estat\u00edsticos, pois sem a sua \n\ninfinita disposi\u00e7\u00e3o em ajudar o pr\u00f3ximo esta disserta\u00e7\u00e3o n\u00e3o teria sido conclu\u00edda.  \n\nAos funcion\u00e1rios do Departamento de Bioqu\u00edmica, em especial Miron e Neide, \n\npois foram pessoas especiais e marcantes em minha passagem por este departamento.  \n\nAos funcion\u00e1rios do LIKA Sr. Otaviano, Carmelita, Mois\u00e9s, Ilma, Concei\u00e7\u00e3o, \n\nFelipe e Rafael pela coopera\u00e7\u00e3o diante das tarefas di\u00e1rias. \n\nAs minhas grandes amigas, Constantina Dimou e Arlinda Leite, que me \n\najudaram de forma sublime ao longo das in\u00fameras dificuldades em minha vida pessoal; \n\n Ao CNPq, Rede Nanobiotec-MCT/CNPq e BNB pelo suporte financeiro na \n\nrealiza\u00e7\u00e3o desta disserta\u00e7\u00e3o.   \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n\u00cdNDICE ANAL\u00cdTICO \nP\u00e1ginas  \n\nAGRADECIMENTOS................................................................................................................  \n \nLISTA DE FIGURAS.................................................................................................................  \n \nLISTA DE TABELAS ............................................................................................................... \n \nABREVIATURAS ...................................................................................................................... \n \nRESUMO ....................................................................................................................................  \n \nABSTRACT................................................................................................................................. \n \n1. INTRODU\u00c7\u00c3O....................................................................................................................... \n \n\n1.1. C\u00e2ncer .................................................................................................................................. \n\n1.1.1. Epidemiologia..................................................................................................................... \n\n1.1.2. Cancerologia Experimental................................................................................................. \n\n1.1.3. Tratamento.......................................................................................................................... \n\n1.2. Sistemas de Libera\u00e7\u00e3o Controlada de F\u00e1rmacos.............................................................. \n\n1.2.1. Sistemas Nanoparticulados................................................................................................. \n\n1.2.1.1. Nanopart\u00edculas (nanoesferas e nanoc\u00e1psulas).................................................................. \n\n1.2.1.1.1. Aplica\u00e7\u00f5es Biol\u00f3gicas................................................................................................... \n\n1.2.1.1.2. Atualidades.................................................................................................................... \n\n1.2.1.1.3. Nanopart\u00edculas na Terapia do C\u00e2ncer .......................................................................... \n\n1.2.1.2. Nanoc\u00e1psulas................................................................................................................... \n\n1.2.2. Microemuls\u00f5es.................................................................................................................... \n\n1.3. L\u00edquens.................................................................................................................................. \n\n1.3.1. Fun\u00e7\u00e3o Biol\u00f3gica dos L\u00edquens............................................................................................ \n\n1.3.2. \u00c1cido Fumarprotocetr\u00e1rico................................................................................................. \n\n1.3.2.1. Estrutura Qu\u00edmica Molecular........................................................................................... \n\n1.3.2.2. Caracter\u00edsticas F\u00edsico-Qu\u00edmicas....................................................................................... \n\n1.3.2.3. Ocorr\u00eancia........................................................................................................................ \n\n1.3.2.4. Aplica\u00e7\u00f5es Biologicas......................................................................................................  \n\n1.3.2.4.1. Atividade Antibacteriana.............................................................................................. \n\n1.3.2.4.2. Atividade Antimicobacteriana...................................................................................... \n\n1.3.2.4.3. Atividades Citot\u00f3xica e Antitumoral............................................................................ \n\n1.4. Mecanismo de A\u00e7\u00e3o Proposto do \u00c1cido Fumarprotocetr\u00e1rico....................................... \n\n2. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS.................................................................................. \n\ni \n \nv \n \n\nvi \n \n\nvii \n \n\nvii \n \nx \n\n   \n\n  01 \n\n  01 \n\n  02 \n\n  02 \n\n  03 \n\n  05 \n\n  06 \n\n  06 \n\n  08 \n\n  09 \n\n  10 \n\n  11 \n\n  13 \n\n  14 \n\n  14 \n\n  15 \n\n  15 \n\n  16 \n\n  16 \n\n  17 \n\n  17 \n\n  18 \n\n  18 \n\n  19 \n\n  20 \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n3. OBJETIVOS............................................................................................................................ \n\n3.1. Objetivo Geral........................................................................................................................ \n\n3.2. Objetivos Espec\u00edficos............................................................................................................. \n\n4. ARTIGO.................................................................................................................................. \n \n\n5. CONCLUS\u00d5ES....................................................................................................................... \n \nANEXOS ..................................................................................................................................... \n \nANEXO I \n \nParecer do Comit\u00ea de \u00c9tica \n \n \nANEXO II \n \nNormas para publica\u00e7\u00e3o do trabalho no International Journal of Pharmaceutics \n\n27 \n\n27 \n\n27 \n\n28 \n\n48 \n\n49 \n\n \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \nLISTA DE FIGURAS \n\n \n \n\nP\u00e1ginas  \nREVIS\u00c3O BIBLIOGR\u00c1FICA \n \n\nFigura 1: A\u00e7\u00e3o dos agentes carcinog\u00eanicos no DNA............................................................... \n\nFigura 2: Perfis de libera\u00e7\u00e3o de f\u00e1rmacos em fun\u00e7\u00e3o do tempo: convencional \u00d7 controlada.. \n\nFigura 3: Exemplos das diversas formas farmac\u00eauticas: (A) esfera (sistema matricial) e (B) \n\nc\u00e1psula (sistema reservat\u00f3rio)................................................................................................... \n\nFigura 4: Formas de libera\u00e7\u00e3o do princ\u00edpio ativo: nanoesferas e nanoc\u00e1psulas...................... \n\nFigura 5: M\u00e9todo de copolimeriza\u00e7\u00e3o interfacial para se preparar nanoc\u00e1psulas.................... \n\nFigura 6: Microestrutura do talo liqu\u00eanico: (A) Fotobionte; (B) Hifas medulares ou \n\nmedula; (C) Hifas corticais ou c\u00f3rtex superior.......................................................................... \n\nFigura 7: Estrutura qu\u00edmica do \u00e1cido fumarprotocetr\u00e1rico...................................................... \n\nFigura 8: Talo liqu\u00eanico da Cladonia verticillaris................................................................... \n\n \nARTIGO \n \nFigure 1: The pH evolution for nanocapsule formulations: ( ) FPA-NC, and ( ) FPA-\n\nNC/ME stored at 4 \u00b11\u00b0C........................................................................................................... \n\nFigure 2: In vitro kinetic profile of FPA-loaded nanocapsules prepared with o/w microemul \n\n-sion (FPA NC/ME).................................................................................................................. \n\nFigure 3: The cytotoxic effect of the treatment with FPA-loaded nanocapsules with or \n\nwithout oil-in-water microemulsion on (A) NCI-H 292 and (B) Hep-2 cells........................... \n\nFigure 4: Histopathological aspect of animal organs after treatments with with free FPA (I) \n\nand FPA-loaded nanocapsules with o/w microemulsion (II): (a) spleen, (b) liver and (c) \n\nkidneys. The magnificence was 20\u00d7 (  arrays denote area of necrosis)............................... \n\nFigure 5: Evaluation of tumor weight after treatment with FPA, unloaded-nanocapsules \n\nand FPA-loaded nanocapsules (FPA-NC), without o/w microemulsion................................... \n\nFigure 6: Evaluation of the antitumor activity of FPA-loaded nanocapsules against \n\nSarcoma-180: free FPA and FPA-loaded nanocapsules (FPA-NC), without o/w \n\nmicroemulsion........................................................................................................................... \n\nFigure 7: Histopathological aspect of animal organs after treatments with with free FPA (I) \n\nand FPA-loaded nanocapsules without o/w microemulsion (II): (a) spleen, (b) liver and (c) \n\nkidneys. The magnificence was 50\u00d7 ......................................................................................... \n\n \n \n   \n  02 \n \n  05 \n\n   \n  07 \n\n  07 \n \n  12 \n \n \n  14 \n \n\n  16 \n \n\n  17 \n \n \n \n \n   \n  39 \n \n \n  40 \n \n \n  41 \n \n \n \n \n  42 \n \n \n  43 \n \n \n \n \n\n  43 \n \n \n   \n \n\n44 \n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nLISTA DE TABELAS \n \nARTIGO \n \n \nTable 1. The nature and concentration of constituents in nanocapsule formulations............... \n \n \n \n \n \n\n \n \n \n \n \n\n38 \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \nLISTA DE ABREVIATURAS \n\n \n \n \n\nCLAE - Cromatografia L\u00edquida de Alta Efici\u00eancia \u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\nDrug Delivery Systems \u2013 Sistemas de Libera\u00e7\u00e3o de F\u00e1rmacos  \n\nFDA \u2013 Administra\u00e7\u00e3o de F\u00e1rmacos e Alimentos \n\nFPA - \u00c1cido Fumarprotocetr\u00e1rico \n\nFPA-NC - Nanoc\u00e1psulas contendo o \u00e1cido fumarprotocetr\u00e1rico  \n\nFPA-NC/ME \u2013 Nanoc\u00e1psulas, contendo o \u00e1cido fumarprotocetr\u00e1rico, preparadas \n\ncom a microemuls\u00e3o O/A  \n\nHEp-2 \u2013 Carcinoma epiderm\u00f3ide de laringe  \n\nHIV-1 \u2013 V\u00edrus da Imunodefici\u00eancia Humana \u20131 \n\nHSV \u2013 V\u00edrus do Herpes \n\nHPV - Papiloma V\u00edrus Humano  \n\nINCA - Instituto Nacional do C\u00e2ncer \n\nME \u2013 Microemuls\u00e3o O/A \n\nNC/ME \u2013 Nanoc\u00e1psulas preparadas com a microemuls\u00e3o O/A \n\nPCR \u2013 Prote\u00edna C Reativa \n\nPEG - Polietilenoglicol \n\nPLGA- Copol\u00edmero de \u00e1cido l\u00e1tico e glic\u00f3lico \n\nMEM - Meio M\u00ednimo Essencial  \n\nM5076 \u2013 Sarcoma ovariano \n\nMDA-MB 231- Carcinoma de mama humano  \n\nNCI-H 292 \u2013 C\u00e9lulas de c\u00e2ncer de pulm\u00e3o humano  \n\nSNC \u2013 Sistema Nervoso Central \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n \n\nRESUMO \n \n \n\nNanopart\u00edculas s\u00e3o carreadores coloidais polim\u00e9ricos utilizados como sistemas \nde libera\u00e7\u00e3o controlada de f\u00e1rmacos e podem agir como um ve\u00edculo carreador de \nf\u00e1rmaco capaz de atingir tecidos ou c\u00e9lulas tumorais, enquanto protege a inativa\u00e7\u00e3o \nprematura do princ\u00edpio ativo durante o seu transporte. O \u00e1cido fumarprotocetr\u00e1rico \n\n(FPA), uma depsidona ?-orcinol, \u00e9 considerado um metab\u00f3lito secund\u00e1rio \nbiologicamente ativo da esp\u00e9cie de l\u00edquens Cladonia verticillaris, pois as atividades \nantibacteriana, antimicobacteriana e antitumoral t\u00eam sido atribu\u00eddas a este \u00e1cido. As \nmicroemuls\u00f5es s\u00e3o potentes sistemas carreadores de f\u00e1rmacos para as administra\u00e7\u00f5es \noral, t\u00f3pica e parenteral, pois oferecem v\u00e1rias vantagens, tais como: forma\u00e7\u00e3o \nespont\u00e2nea, estabilidade termodin\u00e2mica, melhoramento da solubiliza\u00e7\u00e3o e \nbiodisponibilidade do f\u00e1rmaco. O objetivo deste trabalho baseia-se na investiga\u00e7\u00e3o das \natividades citot\u00f3xica, t\u00f3xica e antitumoral de nanoc\u00e1psulas de copol\u00edmero de \u00e1cido \nl\u00e1tico e glic\u00f3lico (PLGA-50/50), contendo o \u00e1cido fumarprotocetr\u00e1rico. As \nnanoc\u00e1psulas, obtidas pelo m\u00e9todo de deposi\u00e7\u00e3o interfacial de copol\u00edmero pr\u00e9-formado, \nforam preparadas sem (FPA-NC) e com o sistema de microemuls\u00e3o O/A (FPA-\nNC/ME), como fase oleosa interna. Os par\u00e2metros f\u00edsico-qu\u00edmicos e de estabilidade \ndestas prepara\u00e7\u00f5es tamb\u00e9m foram analisados, tais como: altera\u00e7\u00f5es de pH; doseamento \nqu\u00edmico e determina\u00e7\u00e3o da taxa de encapsula\u00e7\u00e3o. O perfil cin\u00e9tico de libera\u00e7\u00e3o in vitro, \nfoi obtido pelo m\u00e9todo de di\u00e1lise direta. Os ensaios de citotoxicidade do FPA livre e \nencapsulado foram realizados frente \u00e0s linhagens celulares, NCI-H 292 e HEp-2, \ncultivadas em meio MEM (Meio M\u00ednimo Essencial). A atividade antitumoral foi \navaliada frente ao tumor s\u00f3lido Sarcoma 180, em camundongos Swiss, sendo a inibi\u00e7\u00e3o \ntumoral calculada pela compara\u00e7\u00e3o dos pesos m\u00e9dios dos tumores dos grupos tratado e \ncontrole, respectivamente. Os ensaios de toxicidade in vivo do FPA em suas formas, \nlivre e encapsulada, foram averiguados durante 8 semanas, ap\u00f3s o tratamento di\u00e1rio, \nutilizando a dose de 11 mg.Kg-1. Ao t\u00e9rmino do tratamento, os animais foram \nsacrificados e os \u00f3rg\u00e3os (ba\u00e7o, f\u00edgado e rins) foram dissecados e submetidos \u00e0s an\u00e1lises \nhistopatol\u00f3gicas. As formula\u00e7\u00f5es FPA-NC/ME apresentaram uma consider\u00e1vel \nestabilidade em compara\u00e7\u00e3o com as formula\u00e7\u00f5es obtidas sem este sistema, ou seja, \npermaneceram est\u00e1veis ap\u00f3s os ensaios de estabilidade acelerada. Quanto ao estudo do \npH, ao longo do tempo (60 dias), n\u00e3o foi evidenciada varia\u00e7\u00e3o significativa em ambas \nformula\u00e7\u00f5es estudadas, FPA-NC (7,37 a 6,65) e FPA-NC/ME (7,43 a 6,88), por\u00e9m \napresentaram taxas de encapsula\u00e7\u00e3o distintas do princ\u00edpio ativo, ou seja, 49,5% e \n86,2%, respectivamente. O perfil cin\u00e9tico de libera\u00e7\u00e3o in vitro do FPA a partir das \nnanoc\u00e1psulas/microemuls\u00e3o (NC/ME) exibiu uma libera\u00e7\u00e3o m\u00e1xima de 40,8% nas \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nprimeiras 4 horas, considerando-se 86,2% da concentra\u00e7\u00e3o te\u00f3rica do FPA encapsulado. \nA viabilidade das c\u00e9lulas NCI-H 292 tratadas com FPA, NC e FPA-NC foram \n\nobservadas at\u00e9 a  concentra\u00e7\u00e3o de 50 \u00b5g.mL-1, todavia as c\u00e9lulas tratadas com FPA/ME \n\napresentaram na concentra\u00e7\u00e3o de 6,25 \u00b5g.mL-1(25% de viabilidade celular) uma elevada \ncitotoxicidade. Entretanto, as c\u00e9lulas tratadas com o sistema  FPA-NC/ME apresentaram \n\numa redu\u00e7\u00e3o do efeito citot\u00f3xico, permitindo a determina\u00e7\u00e3o da IC50 a 12,5 \u00b5g.mL-1. \nEm rela\u00e7\u00e3o as c\u00e9lulas  HEp-2, a viabilidade celular foi preservada ap\u00f3s o tratamento \n\ncom FPA, NC e FPA-NC at\u00e9 a concentra\u00e7\u00e3o de 50 \u00b5g.mL-1, sendo que as c\u00e9lulas \n\ntratadas com FPA/ME apresentaram toxicidade a 6,25 \u00b5g.mL-1 (~35% viabilidade \ncelular). Contrariamente, o sistema FPA-NC/ME apresentou uma redu\u00e7\u00e3o do efeito  \ncitot\u00f3xico. Estes resultados demonstram que o FPA livre e nanoencapsulado, sem o \nsistema de microemuls\u00e3o O/A, n\u00e3o apresentaram a\u00e7\u00e3o citot\u00f3xica sobre as linhagens \ncelulares estudadas, NCI-H 292 e HEp-2. O perfil de toxicidade in vivo foi analisado, \natrav\u00e9s da an\u00e1lise histopatol\u00f3gica dos \u00f3rg\u00e3os ba\u00e7o, f\u00edgado e rins tratados com o FPA e \nFPA-NC/ME. O aspecto morfol\u00f3gico das c\u00e9lulas espl\u00eanicas manteve-se inalterado, ap\u00f3s \no tratamento do FPA em suas formas livre e encapsulada, por\u00e9m o f\u00edgado e os rins \ndemonstraram les\u00f5es significativas, tais como: necrose nos hepat\u00f3citos e uma \nglomerulonefrite mesangioproliferativa, respectivamente. No estudo da atividade \nantitumoral evidenciou-se que a quimioterapia realizada, durante 7 dias, com FPA-NC \napresentou uma inibi\u00e7\u00e3o tumoral de 61,4%, quando comparado com a sua forma livre \n(58,9%), frente ao Sarcoma 180. Altera\u00e7\u00f5es histopatol\u00f3gicas nos tecidos, espl\u00eanico, \nhep\u00e1tico e renal n\u00e3o foram evidenciadas, ap\u00f3s o tratamento com o FPA em suas formas \nlivre e encapsulada, quando comparadas ao grupo controle. Estes resultados indicam \nque a nanoencapsula\u00e7\u00e3o continua sendo uma alternativa para a aplica\u00e7\u00e3o terap\u00eautica de \nf\u00e1rmacos com a\u00e7\u00e3o anticancer\u00edgena, tanto para a obten\u00e7\u00e3o de uma melhor efic\u00e1cia \nterap\u00eautica quanto para a minimiza\u00e7\u00e3o dos efeitos t\u00f3xicos. \n\n \n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \nABSTRACT \n\n \nThe potential of controlled release in optyimizing drug targeting has offered a \n\ntremendous advancement in the manipulation of novel dosage forms such as \n\nnanoparticles, wich are solid colloidal polymeric carriers in size range of 1-1,000 nm. \n\nOil-in-water microemulsions as a drug delivery system include improvement of drug \n\nsolubilization. The fumarprotocetraric acid, a ?-orcinol depsidone, is obtained from \n\nCladonia verticillaris and its antibacterial,  antimycobacterial  and antitumor activities \n\nhad been evaluated. The main purpose of this work is to investigate the cytotoxicity, \n\ntoxicity and antitumor activity of free and fumarprotocetraric acid (FPA) encapsulated \n\ninto PLGA-nanocapsules prepared by interfacial deposition of a pre-formed copolymer \n\nmethod. The physicochemical and stability parameters of the nanocapsules were also \n\ninvestigated. The cytotoxic effect of FPA on different forms, free (FPA) and \n\nencapsulated with and without oil-in-water  microemulsion (FPA-NC and FPA-\n\nNC/ME), respectively, was evaluated on human lung cancer (NCI-H 292) and larynx \n\nepidermoid carcinoma (HEp-2) cells line cultured in MEM (Minimum Essential \n\nMedium). The toxicity was analized on Swiss mice with a daily treatment for 8 weeks. \n\nAfter treatment, animals were sacrificed and their organs (liver, kidneys, and spleen) \n\nwere submitted to histopathological analysis. The analysis of the antitumor activity was \n\nassessed against solid tumor Sarcoma 180 in Swiss mice, and was estimated by the \n\ntumor inhibition. Results showed that the encapsulation efficiency of the \n\nfumarprotocetraric acid into PLGA-nanocapsules in different carriers was 49.5% (FPA-\n\nNC) and 86.2% (FPA-NC/ME), respectively. The kinetic profile of FPA from \n\nnanocapsule-microemulsion formulation presented a gradual augmentation of the drug \n\nrelease, achieveing 40.8% at a 4 hours. The viability of NCI-H 292 cells treated with \n\nFPA, NC and FPA-loaded nanocapsules was maintained even at 50 \u00b5g.mL-1. In \n\ncontrast, the cell treatment with o/w microemulsion (ME) or FPA-ME promoted a high \n\ncytotoxicity at 6.25 \u00b5g.mL-1 (25% cell viability). Concerning HEp-2 cells, their viability \n\nwas preserved after treatment with FPA, NC or  FPA-NC even at  50 \u00b5g.mL-1. Results \n\nshowed that FPA have no cytotoxic effects on NCI-H 292 or HEp-2 cells, and FPA-\n\nloaded nanocapules have no cytotoxic effect on NCI-H 292 cells. In contrast, the o/w \n\nmicroemulsion exhibited a high cytotoxicity on both cells. No behavioral alterations \n\nwere observed in animals during the toxicity assay of FPA formulations. No statiscally \n\nsignificant difference in body weight was detected for animals treated with free and \n\nencapsulated FPA in relation to the control group. However the treatment with FPA \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nencapsulated in NC/ME promoted pronounced injuries in liver and kidneys of animals. \n\nCellular and renal tubules necroses were detected in kidneys. The antitumor activity \n\npromoted by free FPA, unloaded-nanocapsules and FPA-loaded nanocapsules evaluated \n\non Sarcoma 180-bearing mice promoted 61.4% of tumor inhibition when compared with \n\nfree FPA (58.9%) in relation to the control group. \n\nResults showed that encapsulation of fumarprotocetraric acid into PLGA-\n\nnanocapsules can be a potential alternative to allow in a diversity of therapeutical \n\napplications. The nanoencapsulation with microemulsion can therefore be considered as \n\na potential alternative to improve solubilization of lichens metabolites, such as \n\nfumarprotocetraric acid. However microemulsions prepared with Cremophor?  \n\nexhibited a substancial in vitro and in vivo toxicity. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n1. INTRODU\u00c7\u00c3O \n\n \n1.1. C\u00e2ncer \n \n\nO c\u00e2ncer \u00e9 causado em quase todos os casos por muta\u00e7\u00e3o ou por ativa\u00e7\u00e3o anormal \n\nde genes celulares que controlam o crescimento e a mitose celular. Estes genes anormais \n\ns\u00e3o chamados de oncogenes (Guyton &amp; Hall, 2002). \n\nC\u00e2ncer (do latim CANCER - Caranguejo) \u00e9 uma tradu\u00e7\u00e3o latina da palavra grega \n\ncarcinoma (KRVKINOS) que tem o mesmo significado. Esta palavra \u00e9 utilizada para \n\ndesignar os tumores malignos, desde os povos antigos, e teve sua origem decorrente da \n\nsemelhan\u00e7a com o referido crust\u00e1ceo, pelo seu car\u00e1ter infiltrativo. Galeno utilizou-a \n\npela primeira vez, aproximadamente 138-201 a.C., para indicar um tumor maligno da \n\nmama em que as veias superficiais desses \u00f3rg\u00e3os apareciam intumescidas, \n\nassemelhando-se \u00e0 pata de caranguejo (Murrad &amp; Katz, 1996).  \n\nHoje est\u00e1 claro que o c\u00e2ncer \u00e9 uma doen\u00e7a gen\u00e9tica, pois como todas as c\u00e9lulas de \n\num tumor possuem o oncogene pode-se concluir que o tumor \u00e9 um clone mutante. Os \n\noncogenes normalmente desempenham fun\u00e7\u00f5es celulares b\u00e1sicas, em geral relacionadas \n\n\u00e0 regula\u00e7\u00e3o da multiplica\u00e7\u00e3o celular. Entretanto, v\u00e1rios tipos de eventos podem \n\ntransformar um proto-oncogene em um oncogene, estado no qual ele promove as duas \n\nprincipais caracter\u00edsticas do c\u00e2ncer: multiplica\u00e7\u00e3o celular descontrolada, levando a um \n\ncrescimento excessivo de um grupo de c\u00e9lulas chamado de tumor e a dispers\u00e3o de \n\nc\u00e9lulas pelo corpo para formar novos tumores, um processo chamado met\u00e1stase \n\n(Griffiths et al., 1998). \n\n O c\u00e2ncer pode surgir n\u00e3o apenas em decorr\u00eancia da ativa\u00e7\u00e3o de oncogenes \n\npromotores do crescimento, mas tamb\u00e9m devido \u00e0 inativa\u00e7\u00e3o de genes que normalmente \n\nsuprimem a prolifera\u00e7\u00e3o celular (genes supressores do c\u00e2ncer ou anti-oncogenes) \n\n(Robbins et al., 2001).     \n\nCarcinog\u00eanese e/ou oncog\u00eanese s\u00e3o termos que designam o processo de \n\ndesenvolvimento de uma neoplasia, desde as altera\u00e7\u00f5es mais precoces no DNA, que \n\nsupostamente ocorrem em uma s\u00f3 c\u00e9lula ou em um pequeno grupo delas, at\u00e9 a forma\u00e7\u00e3o \n\nde um tumor que pode destruir o organismo hospedeiro. Este processo neopl\u00e1sico \u00e9 um \n\nprocesso din\u00e2mico, que evolui em m\u00faltiplas etapas (Montenegro &amp; Franco, 1999) \n\n(Figura 1).   \n\n \n\n \n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n \n \n \n \n\n \n \n \n \n \n\n \n \n \n\nFigura 1: A\u00e7\u00e3o dos agentes carcinog\u00eanicos no DNA \n(http://press2.nci.nih.gov/sciencebehind/cioc/molecular/30.1.jpg) \n\n \n \n1.1.1. Epidemiologia \n\n \nAtualmente, o c\u00e2ncer \u00e9 considerado a segunda causa de morte no Brasil e em 1994, \n\nos neoplasmas foram respons\u00e1veis por 10,86% dos 887. 594 \u00f3bitos registrados, sendo \n\nque 53,81% dos \u00f3bitos por neoplasia ocorreram entre homens e 46,05%, entre as \n\nmulheres (Minist\u00e9rio da Sa\u00fade/INCA, 2003). \n\nNa Regi\u00e3o Nordeste, as neoplasias representam a terceira causa de morte por \n\ndoen\u00e7a, consistindo de 6,34% dos \u00f3bitos atestados, ficando apenas 0,02 pontos \n\npercentuais depois das doen\u00e7as infecciosas e parasit\u00e1rias. Pernambuco apresenta uma \n\ntaxa bruta de incid\u00eancia de neoplasias estimada em 112,69 casos para homens e 146,42 \n\ncasos para mulheres, no ano de 2003, para cada 100.000 indiv\u00edduos (Minist\u00e9rio da \n\nSa\u00fade/INCA, 2003). \n\nAs taxas de sobrevida de todos os c\u00e2nceres v\u00eam aumentando continuamente nos \n\n\u00faltimos 20 anos, tendo sido geralmente maior para as mulheres do que para os homens. \n\nAs taxas de sobrevida atuais relativas a cinco anos, para todos os c\u00e2nceres, aumentaram \n\nde 18% para 29% nos homens e de 33% para 43% nas mulheres, entre 1970 e 1990 \n\n(Spence &amp; Johnston, 2003). \n\n \n\n1.1.2. Cancerologia Experimental \n\n \n\nTradicionalmente, os f\u00e1rmacos utilizados para o tratamento do c\u00e2ncer foram   \n\ndescobertos atrav\u00e9s da triagem, em grande escala, de subst\u00e2ncias qu\u00edmicas de s\u00edntese e \n\njjjjjjjjjjjjjj \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\nhttp://press2.nci.nih.gov/sciencebehind/cioc/molecular/30.1.jpg\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nprodutos naturais contra sistemas tumorais em animais, principalmente leucemias \n\nmurinas (Hardman &amp; Limbird, 1996). \n\nA realiza\u00e7\u00e3o de testes in vivo e in vitro para detectar a atividade antitumoral de \n\nnovas subst\u00e2ncias \u00e9 de vital import\u00e2ncia para a descoberta de novos quimioter\u00e1picos. \n\nTestes in vivo aplicados \u00e0 cancerologia experimental t\u00eam sido os mais recomend\u00e1veis, \n\napesar de serem dispendiosos e com respostas n\u00e3o muito r\u00e1pidas (Rodrigues, 2001). \n\nEstes ensaios permitem a an\u00e1lise de um grande n\u00famero de amostras, viabilizando a \n\nlocaliza\u00e7\u00e3o dos princ\u00edpios ativos em determinadas fra\u00e7\u00f5es obtidas durante o processo de \n\nextra\u00e7\u00e3o de produtos de origem natural (Favaro et al., 1990).  \n\nCarreadores coloidais tais como os lipossomas e nanopart\u00edculas t\u00eam sido \n\nfreq\u00fcentemente utilizados para a libera\u00e7\u00e3o intravenosa de agentes anti-cancer\u00edgenos \n\npara tumores s\u00f3lidos, devido ao r\u00e1pido seq\u00fcestro desses carreadores pelos macr\u00f3fagos \n\nno f\u00edgado e ba\u00e7o (Laverman et al.,  2001). \n\n \n\n1.1.3. Tratamento \n\n \n\nDevido \u00e0 import\u00e2ncia epidemiol\u00f3gica dos processos neopl\u00e1sicos, in\u00fameras \n\nabordagens terap\u00eauticas v\u00eam sendo investigadas. As categorias b\u00e1sicas para o \n\ntratamento s\u00e3o: cirurgia, radioterapia e quimioterapia. Esta \u00faltima apresenta aspecto \n\ndesfavor\u00e1vel, devido \u00e0 inespecificidade do f\u00e1rmaco e \u00e0 dificuldade em se estabelecer \n\numa dose efetiva para destruir o m\u00e1ximo de c\u00e9lulas com o m\u00ednimo de efeitos colaterais \n\npara as c\u00e9lulas normais (Santos, 2003). Segundo o Minist\u00e9rio da Sa\u00fade/INCA (2003), a \n\nhormonioterapia, a imunoterapia e as terap\u00eauticas combinadas tamb\u00e9m s\u00e3o alternativas \n\ndispon\u00edveis para o tratamento do c\u00e2ncer. \n\n O potencial para tratar pacientes de c\u00e2ncer pelas abordagens imunol\u00f3gicas se \n\nmostra muito promissor para os imunologistas e oncobi\u00f3logos, pois a imunoterapia tem \n\no potencial de ser o tratamento mais espec\u00edfico planejado para os tumores, devido \u00e0 \n\nutiliza\u00e7\u00e3o \u00fatil de anticorpos monoclonais tumor-espec\u00edficos (Abbas et al., 2000; Abbas \n\net al., 2003). O sistema imunol\u00f3gico necessita enfrentar as extremas dificuldades em \n\ndesempenhar sua fun\u00e7\u00e3o de reconhecimento e destrui\u00e7\u00e3o das c\u00e9lulas tumorais, pois as \n\nmesmas exibem muitas semelhan\u00e7as com as c\u00e9lulas normais, apesar da sua tend\u00eancia \n\nanormal de prolifera\u00e7\u00e3o (Stites et al., 1997).   \n\nUm marco muito importante no desenvolvimento racional de f\u00e1rmacos direcionados \n\ncontra oncogenes espec\u00edficos foi alcan\u00e7ado em 1988, quando o FDA aprovou a \n\nHerceptina, um anticorpo monoclonal contra a prote\u00edna oncog\u00eanica Erb-2, para o \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\ntratamento de c\u00e2ncer metast\u00e1tico de mama (Cooper, 2001). A Biologia Molecular est\u00e1 \n\ncome\u00e7ando a fornecer ferramentas para encontrar de forma precisa quais genes s\u00e3o \n\namplificados, deletados e mutados em c\u00e9lulas tumorais em um determinado paciente, \n\nassim podendo provar a sua import\u00e2ncia no acompanhamento e preven\u00e7\u00e3o do c\u00e2ncer \n\n(Alberts et al., 1997). Podendo-se antecipar que a metodologia baseada na prote\u00edna C \n\nreativa (PCR) tornar-se-\u00e1 um procedimento de diagn\u00f3stico rotineiro tanto no \n\nrastreamento de predisposi\u00e7\u00e3o do c\u00e2ncer quanto no monitoramento dos pacientes, \n\nvisando o planejamento da sua terapia (Henry, 1999). \n\nA maioria dos f\u00e1rmacos utilizados atualmente no tratamento de c\u00e2ncer ou danificam \n\no DNA ou inibem a sua replica\u00e7\u00e3o. Uma nova abordagem promissora para a terapia do \n\nc\u00e2ncer \u00e9 o uso de f\u00e1rmacos capazes de inibir o crescimento do tumor por interferir com \n\na angiog\u00eanese (forma\u00e7\u00e3o dos vasos sang\u00fc\u00edneos), em vez de atuarem diretamente contra \n\nas c\u00e9lulas cancerosas (Cooper, 2001). Mediadores da angiog\u00eanese e prote\u00ednas que t\u00eam \n\nexpress\u00e3o regulada, em vasos sang\u00fc\u00edneos rec\u00e9m-formados, tais como as integrinas ?v?3 \n\ne ?v?5, representam alvos farmacol\u00f3gicos potentes para a terapia anti-angiog\u00eanica \n\n(Reynolds et al., 2003). Al\u00e9m disso, pesquisas est\u00e3o sendo desenvolvidas para a \n\nprodu\u00e7\u00e3o de f\u00e1rmacos capazes de inibir as enzimas proteinases, secretadas pelo tumor, \n\n\u00fateis na redu\u00e7\u00e3o do crescimento celular e desenvolvimento neopl\u00e1sico (Stone &amp; \n\nDarlington, 2000).  \n\nAs c\u00e9lulas cancerosas, por crescerem mais rapidamente que as c\u00e9lulas normais da \n\nmaioria dos tecidos, t\u00eam necessidades maiores de nucleot\u00eddeos como precursores na \n\ns\u00edntese de DNA e RNA, assim s\u00e3o, em geral, mais sens\u00edveis aos inibidores da \n\nbioss\u00edntese de nucleot\u00eddeos do que as c\u00e9lulas normais (Nelson &amp; Cox, 2000).     \n\nOs agentes farmacol\u00f3gicos utilizados no tratamento do c\u00e2ncer incluem uma grande \n\nvariedade de compostos que atuam por v\u00e1rios mecanismos, por\u00e9m os agentes \n\natualmente dispon\u00edveis manifestam toxicidade significativa sobre os tecidos normais \n\ncom uma maior complica\u00e7\u00e3o do seu uso, devendo-se considerar criteriosamente o risco \n\nversus benef\u00edcio quando se usam esses agentes (Silva, 2002). Em decorr\u00eancia da \n\ntoxicidade associada aos f\u00e1rmacos anti-cancer\u00edgenos em tecidos normais, uma nova \n\nestrat\u00e9gia tem sido postulada fundamentando-se na associa\u00e7\u00e3o de f\u00e1rmacos antitumorais \n\ncom nanopart\u00edculas coloidais. A utiliza\u00e7\u00e3o de nanocarreadores contendo \n\nanticancer\u00edgenos visa sobrepor os mecanismos de resist\u00eancia celular e n\u00e3o-celular e \n\naumentar a seletividade dos f\u00e1rmacos em c\u00e9lulas cancerosas, enquanto reduz a \n\ntoxicidade em tecidos normais (Brigger et al., 2002). \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n1.2. Sistema de Libera\u00e7\u00e3o Controlada de F\u00e1rmacos \n \n\nO conceito pioneiro de f\u00e1rmacos direcionados a s\u00edtios espec\u00edficos do organismo \n\nfoi postulado por Erlich em 1906, definido como \u201cbalas m\u00e1gicas\u201d. A tecnologia de \n\nsistemas de libera\u00e7\u00e3o de f\u00e1rmacos, como um m\u00e9todo comercialmente atrativo para a sua \n\nadministra\u00e7\u00e3o de forma controlada e s\u00edtio espec\u00edfica, surgiu no in\u00edcio da d\u00e9cada de 80 \n\nEstes tipos de f\u00e1rmacos t\u00eam sido foco de tremenda aten\u00e7\u00e3o, ao longo das \u00faltimas tr\u00eas \n\nd\u00e9cadas, pois o interesse pela manuten\u00e7\u00e3o nos n\u00edveis terap\u00eauticos desses f\u00e1rmacos \n\ncoincide com a aceita\u00e7\u00e3o p\u00fablica e m\u00e9dica de cada sistema (Lachman et al., 2001). \n\nA administra\u00e7\u00e3o de formas farmac\u00eauticas convencionais em doses m\u00faltiplas \n\npromove uma varia\u00e7\u00e3o na concentra\u00e7\u00e3o plasm\u00e1tica do f\u00e1rmaco, atingindo por vezes \n\nn\u00edveis subterap\u00eauticos e t\u00f3xicos durante os intervalos entre as doses (Figura 2). J\u00e1 os \n\nf\u00e1rmacos administrados sob sistema de velocidade controlada, permanecem em \n\nconcentra\u00e7\u00f5es sang\u00fc\u00edneas praticamente constantes, em fun\u00e7\u00e3o do tempo (libera\u00e7\u00e3o \n\nsegundo cin\u00e9tica de ordem zero), ap\u00f3s a administra\u00e7\u00e3o do f\u00e1rmaco em dose \u00fanica. Este \n\nm\u00e9todo vem sendo \u00fatil para o tratamento de s\u00edndromes metab\u00f3licas, tais como a \n\ndiabetes melitus insulino-dependente (Prista et al., 1995; Ansel et al., 2000).  \n\n \n\n \n\n \n\n \n\n \n \n \n \n \n \n \n \n \n \n \n\nFigura 2. Perfis de libera\u00e7\u00e3o de f\u00e1rmacos em fun\u00e7\u00e3o do tempo: convencional \u00d7 controlada \n(http://Lpes.iqm.unicamp.br) \n\n \n\n \n\nOs sistemas de libera\u00e7\u00e3o de f\u00e1rmacos, freq\u00fcentemente descritos como \u201cdrug \n\ndelivery systems\u201d, oferecem in\u00fameras vantagens e desvantagens quando comparados a \n\noutros sistemas de dosagem convencional, tais como (Prista et al., 1995; Lachman et al., \n\n2001): \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\nhttp://lpes.iqm.unicamp.br/\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nI) Vantagens: \n\n \n\n- Diminui\u00e7\u00e3o do n\u00famero de administra\u00e7\u00f5es di\u00e1rias; \n\n- Maior ades\u00e3o do paciente ao tratamento; \n\n- Podem ser interrompidas durante o repouso noturno para as repeti\u00e7\u00f5es das \n\ndoses medicamentosas; \n\n- Minimiza\u00e7\u00e3o dos riscos de erro ou esquecimento, por parte dos pacientes; \n\n- Introdu\u00e7\u00e3o gradual do f\u00e1rmaco, evitando oscila\u00e7\u00f5es, durante o tratamento;   \n\n- Biodisponibilidade aumentada do f\u00e1rmaco; \n\n- Margem de seguran\u00e7a aumentada para f\u00e1rmacos potentes; \n\n- Redu\u00e7\u00e3o dos efeitos adversos. \n\n \n\nII) Desvantagens: \n\n \n\n- Risco de ac\u00famulo do f\u00e1rmaco no organismo, devido \u00e0 velocidade de \n\nelimina\u00e7\u00e3o lenta do mesmo; \n\n- Dificuldade de elimina\u00e7\u00e3o r\u00e1pida dos f\u00e1rmacos, em casos de posologias que \n\nexigem muito rigor; \n\n- N\u00e3o permiss\u00e3o do fim imediato da a\u00e7\u00e3o terap\u00eautica, nos casos de implantes \n\nsubcut\u00e2neos; \n\n- Perda da flexibilidade no ajustamento dos regimes posol\u00f3gicos; \n\n- S\u00e3o concebidas para uma popula\u00e7\u00e3o normal (aus\u00eancia de doen\u00e7a que altere a \n\ndistribui\u00e7\u00e3o e metaboliza\u00e7\u00e3o do f\u00e1rmaco); \n\n- Fatores econ\u00f4micos (dispendiosos); \n\n- Nem todos os f\u00e1rmacos s\u00e3o adequados. \n\n \n1.2.1. Sistemas Nanoparticulados \n\n1.2.1.1. Nanopart\u00edculas (Nanoesferas e Nanoc\u00e1psulas) \n\n \nO potencial de libera\u00e7\u00e3o s\u00edtio-espec\u00edfica, por direcionamento de f\u00e1rmaco, tem \n\nfornecido consider\u00e1veis vantagens na manipula\u00e7\u00e3o de novas formas de dosagens, tais \n\ncomo as nanopart\u00edculas, as quais s\u00e3o carreadores coloidais polim\u00e9ricos s\u00f3lidos com \n\ntamanho de 1-1000 nm (1 \u00b5m) (Gaur et al., 2000).  \n\n Na literatura s\u00e3o citados dois tipos de nanopart\u00edculas: as nanoesferas e as \n\nnanoc\u00e1psulas, cada uma com caracter\u00edsticas pr\u00f3prias. As nanoesferas exibem formato \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nesf\u00e9rico e s\u00e3o constitu\u00eddas por uma rede polim\u00e9rica densa envolvendo toda a estrutura \n\ndas part\u00edculas, enquanto que as nanoc\u00e1psulas s\u00e3o ves\u00edculas s\u00f3lidas que apresentam uma \n\ncavidade interna oca, geralmente de natureza oleosa, estabilizadas por um filme \n\ninterfacial de agentes tensoativos e revestidas, superficialmente, por uma parede \n\npolim\u00e9rica irregular pouca espessa (Couvreur, 1985). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 3: Formas farmac\u00eauticas nanoparticuladas: (A) esfera (sistema matricial) e (B) c\u00e1psua \n\n(sistema reservat\u00f3rio) (http://Lpes.iqm.unicamp.br). \n\n \n \n\nOs sistemas de libera\u00e7\u00e3o controlada do tipo polim\u00e9rico s\u00e3o classificados de \n\nacordo com v\u00e1rios mecanismos de cin\u00e9tica de libera\u00e7\u00e3o, j\u00e1 conhecidos h\u00e1 algum tempo, \n\ntais como: o monol\u00edtico e o reservat\u00f3rio (Figura 4). No sistema s\u00f3lido monol\u00edtico, o \n\nf\u00e1rmaco (princ\u00edpio bioativo) \u00e9 disperso ou dissolvido em um pol\u00edmero inerte e a difus\u00e3o \n\ndo f\u00e1rmaco \u00e9 a etapa limitante, sendo a taxa de libera\u00e7\u00e3o dependente da escolha do \n\npol\u00edmero. Enquanto que, no sistema reservat\u00f3rio o princ\u00edpio bioativo forma uma \n\npart\u00edcula interna (n\u00facleo) envolvida por uma parede de difus\u00e3o inerte (Brannon-Peppas, \n\n1997).  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 4. Mecanismos de libera\u00e7\u00e3o do princ\u00edpio ativo a partir de nanoesferas e nanoc\u00e1psulas \n\n(Brannon-Peppas, 1997). \n\n________________________________________Simonetti, A.C._______________  \n \n\nhttp://lpes.iqm.unicamp.br/\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\n1.2.1.1.1. Aplica\u00e7\u00f5es Biol\u00f3gicas \n\n \n\nAs nanopart\u00edculas tanto podem ser utilizadas como prepara\u00e7\u00f5es de infus\u00e3o \n\nintravascular, emuls\u00f5es injet\u00e1veis para ambas administra\u00e7\u00f5es, parenteral e enteral, assim \n\ncomo formas de dosagem de vacinas para o uso de inje\u00e7\u00f5es subcut\u00e2neas ou \n\nintramusculares (Gibaud et al., 1998; Lemoine &amp; Preat, 1998). Estes sistemas coloidais \n\npolim\u00e9ricos t\u00eam sido propostos como vetores de f\u00e1rmacos no sentido de modificar a sua \n\nfarmacocin\u00e9tica, incluindo a altera\u00e7\u00e3o no perfil de distribui\u00e7\u00e3o tissular, podendo ainda \n\naumentar a biodisponibilidade de muitas susbt\u00e2ncias ativas (Gibaud et al., 1998). \n\nExistem in\u00fameras \u00e1reas promissoras para o emprego de nanopart\u00edculas, tais \n\ncomo a vetoriza\u00e7\u00e3o de f\u00e1rmacos anticancer\u00edgenos; antibi\u00f3ticos; f\u00e1rmacos de origem \n\npept\u00eddica ou prot\u00e9ica; oligonucleot\u00eddeos e de uso de oft\u00e1lmico (Couvreur, 1985). \n\nNanopart\u00edculas podem ser formuladas para uma libera\u00e7\u00e3o s\u00edtio-direcionada do \n\nf\u00e1rmaco no sistema linf\u00e1tico, c\u00e9rebro, paredes arteriais, pulm\u00f5es, f\u00edgado e ba\u00e7o ou para \n\numa circula\u00e7\u00e3o sist\u00eamica prolongada (Hans &amp; Lowman, 2002). Estas utilizadas para \n\ncarrear f\u00e1rmacos para o c\u00e9rebro s\u00e3o de consider\u00e1vel import\u00e2ncia, pois s\u00e3o capazes de \n\nultrapassar a barreira hematoencef\u00e1lica, obst\u00e1culo para um grande n\u00famero de f\u00e1rmacos, \n\ntais como: antibi\u00f3ticos, agentes anti-neopl\u00e1sicos, f\u00e1rmacos do sistema nervoso central \n\n(SNC), especialmente neuropept\u00eddeos (Kreuter, 2001). \n\nA nanoencapsula\u00e7\u00e3o dos oligonucleot\u00eddeos, mol\u00e9culas h\u00e1beis na inibi\u00e7\u00e3o da \n\nexpress\u00e3o g\u00eanica e no tratamento de infec\u00e7\u00f5es virais e/ou c\u00e2ncer, demonstra proteg\u00ea-los \n\nda sua r\u00e1pida degrada\u00e7\u00e3o, promovendo a sua subseq\u00fcente incorpora\u00e7\u00e3o em diferentes \n\ntipos de c\u00e9lulas (Lambert et al., 2001). A incorpora\u00e7\u00e3o de oligonucleot\u00eddeos em \n\ncarreadores polim\u00e9ricos, tais como as nanopart\u00edculas, poder\u00e1 melhorar n\u00e3o apenas a sua \n\nestabilidade e captura, mas como tamb\u00e9m modificar a localiza\u00e7\u00e3o intracelular dos \n\nmesmos (Berton et al., 1999). \n\nCarreadores coloidais nanoparticulados podem agir como um ve\u00edculo carreador \n\nde f\u00e1rmaco capaz de atingir tecidos ou c\u00e9lulas tumorais, enquanto protegem a inativa\u00e7\u00e3o \n\nprematura do mesmo durante o seu transporte (Brigger et al., 2002). A encapsula\u00e7\u00e3o \n\npermite uma melhoria na estabilidade do f\u00e1rmaco, em decorr\u00eancia da sua prote\u00e7\u00e3o \n\n(condi\u00e7\u00f5es de armazenamento) e redu\u00e7\u00e3o dos poss\u00edveis efeitos t\u00f3xicos ou adversos \n\nproduzidos. O principal interesse destes carreadores baseia-se na melhoria do efeito \n\nterap\u00eautico, pelo direcionamento das mol\u00e9culas ativas em seus s\u00edtios de a\u00e7\u00e3o desej\u00e1veis \n\ne pelo ocasionamento de uma elevada concentra\u00e7\u00e3o local (Guinebreti\u00e8re et al., 2002). \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nExistem alguns par\u00e2metros importantes para a efic\u00e1cia da a\u00e7\u00e3o das \n\nnanopart\u00edculas, como carreadores de f\u00e1rmacos, tais como: o tamanho e potencial zeta \n\ndas part\u00edculas, a taxa de encapsula\u00e7\u00e3o do f\u00e1rmaco e as suas caracter\u00edsticas de libera\u00e7\u00e3o, \n\nvisto que podem ser controlados na produ\u00e7\u00e3o farmac\u00eautica (Hans &amp; Lowman, 2002). \n\n \n\n1.2.1.1.2. Atualidades \n\n \n\nRecentemente h\u00e1 um consider\u00e1vel interesse no desenvolvimento de \n\nnanopart\u00edculas furtivas (\u201cStealthTM nanoparticles\u201d), como sistema carreador de f\u00e1rmaco. \n\nEstas nanopart\u00edculas de longa circula\u00e7\u00e3o podem ser preparadas pela modifica\u00e7\u00e3o em sua \n\nsuperf\u00edcie com pol\u00edmeros n\u00e3o-i\u00f4nicos, flex\u00edveis e hidrof\u00edlicos, tais como o \n\npolietilenoglicol (PEG), poloxamers e poloxaminas, promovendo assim a libera\u00e7\u00e3o de \n\nf\u00e1rmacos no reconhecimento e na retifica\u00e7\u00e3o de seus \u00edndices de toxicidade, assim como \n\nna detec\u00e7\u00e3o de doen\u00e7as e desordens vasculares, por m\u00e9todos de imagens m\u00e9dicas \n\n(Moghimi &amp; Hunter, 2000; Li et al., 2001). A presen\u00e7a de poloxamers e poloxaminas, \n\nna superf\u00edcie, diminui a adsor\u00e7\u00e3o prot\u00e9ica (opsoniza\u00e7\u00e3o), a fagocitose das \n\nnanopart\u00edculas pelas c\u00e9lulas n\u00e3o parenquimatosas do f\u00edgado e aumenta o alcance nos \n\ns\u00edtios de infec\u00e7\u00e3o, inflama\u00e7\u00e3o, intravasculariza\u00e7\u00e3o de tumores s\u00f3lidos, e em barreiras \n\nnaturais, tal como a mucosa nasal (Amiji &amp; Park, 2000; Gref et al., 2003). \n\nNanopart\u00edculas magn\u00e9ticas est\u00e3o sendo utilizadas como agentes de contraste em \n\nimagens por resson\u00e2ncia magn\u00e9tica por promovem uma linfotropia adequada, ou seja, \n\nas part\u00edculas s\u00e3o fagocitadas pelos macr\u00f3fagos dentro dos linfonodos promovendo uma \n\nelevada resolu\u00e7\u00e3o de contraste (Brigger et al., 2002). \n\nA especificidade e a longa circula\u00e7\u00e3o promovidas pelas nanopart\u00edculas, em \n\ndeterminados tipos celulares, podem ser alcan\u00e7adas atrav\u00e9s da utiliza\u00e7\u00e3o de ligantes tais \n\ncomo: anticorpos monoclonais, a\u00e7\u00facares, lectinas ou fatores de crescimento. Como \n\nexemplo, pode-se citar as nanopart\u00edculas polim\u00e9ricas furtivas contendo o \n\npolietilenoglicol (PEG) associado com a biotina, vitamina H sol\u00favel em \u00e1gua, e \n\nconjugado com a galactose na superf\u00edcie da part\u00edcula, sendo assim facilmente \n\nendocitadas pelas c\u00e9lulas hep\u00e1ticas tumorais (Barrat, 2000; Kim &amp; Kim, 2003). Estas \n\nnanopart\u00edculas tamb\u00e9m t\u00eam sido reportadas por melhorarem o direcionamento do fator-\n\n? de necrose tumoral recombinante, promovendo um maior ac\u00famulo do f\u00e1rmaco no \n\ntumor (Vauthier et al., 2003).  \n\nOs sistemas de libera\u00e7\u00e3o de f\u00e1rmacos preparados por pol\u00edmeros biodegrad\u00e1veis \n\ns\u00e3o consideravelmente utilizados, devido \u00e0 possibilidade de liber\u00e1-los, sob forma \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\ncontrolada, e de aumentar a sua efic\u00e1cia, enquanto a sua toxicidade \u00e9 reduzida ap\u00f3s a \n\nadministra\u00e7\u00e3o parenteral (Magenheim &amp; Benita, 1991; Julienne et al., 1992). A mais \n\nconhecida classe de materiais biodegrad\u00e1veis para a libera\u00e7\u00e3o controlada \u00e9 a de \n\ncopol\u00edmeros derivados de \u00e1cidos l\u00e1tico e glic\u00f3lico (PLGAs) (Jalil &amp; Nixon, 1990). \n\nAl\u00e9m disso, uma nova classe importante de pol\u00edmeros de poli (\u00e9ter uretano) est\u00e1 sendo \n\nutilizada para a prepara\u00e7\u00e3o de nanoc\u00e1psulas, devido as suas excelentes propriedades \n\nf\u00edsicas (flexibilidade, degrada\u00e7\u00e3o, etc...), resist\u00eancia \u00e0 fibrose e consider\u00e1vel \n\nbiocompatibilidade (Bouchemal et al., 2004).  \n\nConsidera-se ainda que a aplica\u00e7\u00e3o de nanopart\u00edculas polim\u00e9ricas como formas \n\nde dosagens de libera\u00e7\u00e3o controlada de f\u00e1rmacos anticancer\u00edgenos t\u00eam proporcionado \n\nimenso interesse no desenvolvimento de sistemas efetivos para tratamento do c\u00e2ncer \n\n(Soppimath et al., 2001).  \n\n \n\n1.2.1.1.3. Nanopart\u00edculas na Terapia do C\u00e2ncer  \n\n \n\nA a\u00e7\u00e3o terap\u00eautica de f\u00e1rmacos em c\u00e9lulas tumorais \u00e9 eficaz quando alguns \n\nproblemas s\u00e3o superados, tais como: a resist\u00eancia do f\u00e1rmaco, no tumor, devido \u00e0s \n\nbarreiras fisiol\u00f3gicas (mecanismos n\u00e3o-celulares), resist\u00eancia do f\u00e1rmaco na c\u00e9lula \n\n(mecanismo celular), al\u00e9m da distribui\u00e7\u00e3o, biotransforma\u00e7\u00e3o e a excre\u00e7\u00e3o dos f\u00e1rmacos \n\nanticancer\u00edgenos no organismo. A estrat\u00e9gia baseia-se na associa\u00e7\u00e3o destes f\u00e1rmacos \n\ncom nanopart\u00edculas, as quais s\u00e3o capazes de sobrepor estes mecanismos e reduzir, \n\nsubseq\u00fcentemente, a sua toxicidade em tecidos normais (Brigger et al., 2002).    \n\n V\u00e1rios estudos t\u00eam demonstrado que o perfil de distribui\u00e7\u00e3o dos f\u00e1rmacos \n\nanticancer\u00edgenos \u00e9 alterado quando os mesmos s\u00e3o associados \u00e0s nanopart\u00edculas \n\nconvencionais, pois as mesmas s\u00e3o rapidamente removidas da circula\u00e7\u00e3o sang\u00fc\u00ednea pelo \n\nsistema mononuclear fagoc\u00edtico (MPS). Esta captura pelo f\u00edgado e ba\u00e7o reduz a \n\nprobabilidade das nanopart\u00edculas penetrarem nos capilares do tumor, enquanto que os \n\nespa\u00e7os intersticiais tumorais s\u00e3o atingidos (Lambert et al., 2001). \n\n A doxorrubicina \u00e9 um dos f\u00e1rmacos mais prescritos na terapia do c\u00e2ncer, pois \n\nexpressa a sua capacidade citot\u00f3xica pela inibi\u00e7\u00e3o da s\u00edntese dos \u00e1cidos nucl\u00e9icos em \n\nc\u00e9lulas cancerosas (Yoo et al., 2000). Al\u00e9m disso, tem-se observado que a \n\ndoxorrubicina associada \u00e0s nanopart\u00edculas de polialquilcianoacrilato (PACA) \n\ndemonstraram aumentar a sobrevida dos camundongos acometidos por met\u00e1stase \n\nhep\u00e1tica do tumor M5076. Deste modo, prop\u00f4s-se que as c\u00e9lulas de Kupffer \n\ndesempenham uma fun\u00e7\u00e3o reservat\u00f3ria, ap\u00f3s a fagocitose da nanopart\u00edcula, favorecendo \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\na elevada concentra\u00e7\u00e3o do f\u00e1rmaco nas c\u00e9lulas tumorais (Soma et al., 2000). A efic\u00e1cia \n\nterap\u00eautica, em s\u00edtios tumorais, tamb\u00e9m tem sido observada com nanopart\u00edculas de \n\nquitosana contendo a doxorrubicina associada \u00e0 dextrana, uma macromol\u00e9cula inerte e \n\ncarreadora de f\u00e1rmacos quimioter\u00e1picos (Mitra et al., 2001).  \n\n Segundo Singla et al., (2002) e Mu &amp; Feng (2003), as nanopart\u00edculas \n\npolim\u00e9ricas e biodegrad\u00e1veis podem tamb\u00e9m ser adotadas como carreadoras coloidais \n\nde f\u00e1rmacos pouco sol\u00faveis em \u00e1gua, tal como o paclitaxel (Taxol?), um diterpen\u00f3ide \n\npseudoalcal\u00f3ide com mais de 12 000 componentes naturais com atividade \n\nanticancer\u00edgena. Considerando-se a sua elevada hidrofobicidade, as nanopart\u00edculas \n\npromovem a sua maior reten\u00e7\u00e3o nos s\u00edtios tumorais com as subseq\u00fcentes redu\u00e7\u00e3o do \n\ncrescimento tumoral e aumento da sobrevida dos animais tratados.  \n\n \n\n1.2.1.2. Nanoc\u00e1psulas \n\n  \n\nT\u00e9cnicas de nanoencapsula\u00e7\u00e3o resultam em produtos constitu\u00eddos de part\u00edculas \n\nrevestidas que agem como sistemas liberadores de f\u00e1rmaco. Na realidade, as \n\nnanoc\u00e1psulas possuem melhor estabilidade na presen\u00e7a de flu\u00eddos biol\u00f3gicos \n\n(Ammoury, 1990; Stainmesse, 1990) durante o armazenamento e a sua prepara\u00e7\u00e3o \u00e9 \n\napropriada para escala industrial (Colombo et al., 2001).  \n\nAs nanoc\u00e1psulas podem ser consideradas como sendo uma alternativa de \n\nsucesso diante de outros carreadores de mol\u00e9culas ativas (Ammoury, 1990; Stainmesse, \n\n1990), pois o perfil farmacocin\u00e9tico do f\u00e1rmaco \u00e9 modificado, a sua efici\u00eancia \u00e9 \n\naumentada, enquanto que a quantidade administrada e os riscos dos efeitos adversos s\u00e3o \n\ndiminu\u00eddos (Benita, 1996). A mudan\u00e7a no padr\u00e3o de distribui\u00e7\u00e3o \u00e9 vitoriosa, devido ao \n\nendere\u00e7amento espec\u00edfico do princ\u00edpio ativo em seu alvo celular ou a n\u00edvel tecidual \n\n(Couvreur et al., 1982; Grislain et al., 1983).  \n\nSistemas de libera\u00e7\u00e3o nanovesiculares variam em tamanho de 20 a 500 nm \n\nincluindo principalmente lipossomas unilamelares e nanoc\u00e1psulas (Fessi et al., 1989). O \n\nuso das nanoc\u00e1psulas \u00e9 atrativo, devido a sua cavidade central oleosa a qual possibilita \n\num elevado n\u00edvel de encapsula\u00e7\u00e3o de subst\u00e2ncias lipof\u00edlicas como a atovaquone \n\n(Cauchetier et al., 2003). F\u00e1rmacos lipof\u00edlicos, os quais apresentam consider\u00e1vel \n\nsolubilidade na matrix polim\u00e9rica ou na cavidade oleosa das nanoc\u00e1psulas, s\u00e3o mais \n\nrapidamente incorporados em compara\u00e7\u00e3o com os componentes hidrof\u00edlicos, embora \n\nque estes \u00faltimos podem ser absorvidos em n\u00edvel da superf\u00edcie particular (Barrat, 2000). \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nO m\u00e9todo de prepara\u00e7\u00e3o dessas nanoves\u00edculas depende da natureza do f\u00e1rmaco \n\n(hidrof\u00edlico ou lipof\u00edlico) a ser encapsulado (Zambaux et al., 1998). \n\nExistem fatores limitantes na escolha no desenvolvimento de lipossomas, em \n\nrela\u00e7\u00e3o as nanoc\u00e1psulas, tais como: a sensibilidade da membrana fosfolip\u00eddica diante de \n\num ambiente de degrada\u00e7\u00e3o e a r\u00e1pida libera\u00e7\u00e3o do f\u00e1rmaco diante da bicamada lip\u00eddica \n\n(Grit et al., 1989). Adicionalmente, os lipossomas t\u00eam demonstrado uma baixa taxa de \n\nencapsula\u00e7\u00e3o, uma reduzida estabilidade em condi\u00e7\u00f5es de armazenamento e uma r\u00e1pida \n\nlibera\u00e7\u00e3o de f\u00e1rmacos hidrossol\u00faveis no sangue (Soppimath et al., 2001). Enquanto que \n\nas nanoc\u00e1psulas s\u00f3lidas e biodegrad\u00e1veis demonstram suas vantagens sobre os \n\nlipossomas, devido ao seu tamanho extremamente pequeno com o subseq\u00fcente \n\npotencial em se localizar no s\u00edtio patol\u00f3gico, tal como o tumor s\u00f3lido, atrav\u00e9s do \n\nmecanismo passivo de direcionamento. Considera-se ainda, que a sua elevada \n\nestabilidade e a habilidade de criar uma libera\u00e7\u00e3o controlada oferecem op\u00e7\u00f5es \n\nvantajosas (Hans &amp; Lowman., 2002; Singla et al., 2002). \n\nFessi et al., (1989) desenvolveram um m\u00e9todo original denominado de t\u00e9cnica \n\nde deposi\u00e7\u00e3o interfacial para a obten\u00e7\u00e3o de nanoc\u00e1psulas, nanom\u00e9tricas, reprodut\u00edveis, \n\nredispers\u00edveis e formadas instantaneamente, as quais s\u00e3o constitu\u00eddas por um n\u00facleo \n\noleoso coberto por uma fina parede de pol\u00edmero pr\u00e9-formado e biodegrad\u00e1vel. Neste \n\nprocedimento, atrav\u00e9s do deslocamento de um solvente semi-polar misc\u00edvel, acetona, no \n\nqual o pol\u00edmero est\u00e1 inicialmente solubilizado, para a fase aquosa constitu\u00edda de \n\ntamp\u00e3o-fosfato pH 7,4, com conseq\u00fcente deposi\u00e7\u00e3o do pol\u00edmero, agora insol\u00favel, na \n\nsuperf\u00edcie de nanogot\u00edculas emulsificadas, produzindo uma suspens\u00e3o coloidal com \n\nelevada capacidade carreadora de f\u00e1rmacos. Este m\u00e9todo apresenta a vantagem sobre o \n\nm\u00e9todo de polimeriza\u00e7\u00e3o interfacial, devido \u00e0 aus\u00eancia de mon\u00f4meros e olig\u00f4meros dos \n\nreagentes restantes do processo de polimeriza\u00e7\u00e3o (Figura 5) (Gallardo et al., 1989).  \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 5. M\u00e9todo de copolimeriza\u00e7\u00e3o interfacial para se preparar nanoc\u00e1psulas \n\n(http://Lpes.iqm.unicamp.br) \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\nhttp://lpes.iqm.unicamp.br/\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\n1.2.2. MICROEMULS\u00d5ES \n\n \n\nAs microemuls\u00f5es s\u00e3o potentes sistemas carreadores de f\u00e1rmacos para as \n\nadministra\u00e7\u00f5es oral, t\u00f3pica e parenteral. Estas oferecem v\u00e1rias vantagens, tais como:  \n\nforma\u00e7\u00e3o espont\u00e2nea, estabilidade termodin\u00e2mica, melhoramento da solubiliza\u00e7\u00e3o e \n\nbiodisponibilidade do f\u00e1rmaco, assim como a sua libera\u00e7\u00e3o controlada pelas vias de \n\nadministra\u00e7\u00e3o citadas anteriormente. Em decorr\u00eancia da elevada capacidade de \n\nsolubiliza\u00e7\u00e3o e estabilidade termodin\u00e2mica oferecidas pelas microemuls\u00f5es, estes \n\nsistemas farmac\u00eauticos s\u00e3o considerados ve\u00edculos atrativos para a administra\u00e7\u00e3o \n\nparenteral. Na microemuls\u00e3o, o di\u00e2metro das got\u00edculas dispersas varia entre 10 e 75 nm \n\n(Tenjarla, 1999). \n\nA microemuls\u00e3o pode ser de tr\u00eas tipos: (1) \u00f3leo/\u00e1gua (O/A), na qual a \u00e1gua \u00e9 a \n\nfase cont\u00ednua; (2) \u00e1gua/\u00f3leo (A/O), na qual o \u00f3leo \u00e9 a fase cont\u00ednua e (3) bicont\u00ednua, na \n\nqual os volumes de \u00e1gua e \u00f3leo s\u00e3o aproximadamente iguais (Lachman et al., 2001). \n\nRecentemente tem-se reportado que microemuls\u00f5es \u00f3leo/\u00e1gua (O/A), formadas \n\nespontaneamente pela simples mistura de tensoativos, foram preparadas como um \n\nsistema de libera\u00e7\u00e3o de f\u00e1rmacos apresentando algumas vantagens, tais como: a \n\nmelhoria na solubilidade do f\u00e1rmaco; um potencial uso parenteral e produ\u00e7\u00e3o industrial, \n\nem larga escala, sem elevada energia de homogeneiza\u00e7\u00e3o (Park &amp; Kim, 1999). A \n\nlibera\u00e7\u00e3o do princ\u00edpio biativo da microemuls\u00e3o depende de v\u00e1rios par\u00e2metros, tais \n\ncomo: a propor\u00e7\u00e3o de \u00e1gua e \u00f3leo nas fases cont\u00ednua e descont\u00ednua, a distribui\u00e7\u00e3o e a \n\ndifus\u00e3o do f\u00e1rmaco em ambas fases do sistema (Trotta et al., 1989).   \n\nO \u00e1cido clon\u00edxico, pouco sol\u00favel em \u00e1gua, foi incorporado em microemuls\u00f5es \n\n\u00f3leo/\u00e1gua (O/A) visando melhorar a sua solubilidade, com a subseq\u00fcente redu\u00e7\u00e3o da \n\ndor, ap\u00f3s inje\u00e7\u00f5es intramusculares ou intravenosas. Portanto, a formula\u00e7\u00e3o de \n\nmicroemuls\u00e3o pode ser aplicada para f\u00e1rmacos que induzem dor durante inje\u00e7\u00e3o (Lee et \n\nal., 2002). A utiliza\u00e7\u00e3o de microemuls\u00f5es tem sido limitada como ve\u00edculos carreadores \n\nde f\u00e1rmacos para a via ocular, devido a quantidade consider\u00e1vel de tensoativos que \n\npodem eventualmente causar irrita\u00e7\u00e3o na mucosa ocular (Calvo et al., 1996). \n\nAtualmente as microemuls\u00f5es est\u00e3o sendo utilizadas em prepara\u00e7\u00f5es \n\nfarmac\u00eauticas espermicidas, ou seja, como ve\u00edculos de antibi\u00f3ticos ou antivirais capazes \n\nde prevenir doen\u00e7as sexualmente transmiss\u00edveis, tais como o v\u00edrus HIV-1, HSV, HPV e \n\nbact\u00e9rias Neisseria gonorrheae e C. trachomatis (D\u2019Cruz &amp; Uckum, 2001). \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n1.3. L\u00cdQUENS \n\n \n\nL\u00edquens s\u00e3o simbi\u00f3ticos de fungos (micobiontes) e algas (fotobiontes). Estes \n\nproduzem um n\u00famero consider\u00e1vel de componentes org\u00e2nicos, intracelulares e \n\nextracelulares, os quais podem ser facilmente extra\u00eddos de seus tecidos e classificados \n\nde acordo com a sua localiza\u00e7\u00e3o no talo (Figura 6) (Bose &amp; Banerjee, 1976). Os \n\nprodutos intracelulares s\u00e3o carboidratos, caroten\u00f3ides, vitaminas, amino\u00e1cidos e \n\nprote\u00ednas, freq\u00fcentemente sol\u00faveis em \u00e1gua, enquanto que os metab\u00f3litos extracelulares \n\ns\u00e3o compostos resultantes de seu metabolismo secund\u00e1rio, classificados em quatro \n\ngrupos qu\u00edmicos, bioenergeticamente relacionados: deps\u00eddeos, depsidonas, \n\ndibenzofuranos e \u00e1cidos \u00fasnicos (Culberson &amp; Elix, 1972). Estes metab\u00f3litos \n\nsecund\u00e1rios t\u00eam sido mundialmente utilizados farmacologicamente, apesar dos seus \n\nmecanismos de a\u00e7\u00e3o n\u00e3o terem sido completamente elucidados (Yamamoto et al., \n\n1998). \n\n \n\n \n\nFigura 6. Microestrutura do talo liqu\u00eanico: (A) Fotobionte; (B) Hifas medulares;  \n\n(C) Hifas corticais (Oliveira, 2003). \n\n \n\n1.3.1. Fun\u00e7\u00e3o Biol\u00f3gica dos L\u00edquens  \n\n \n\nOs metab\u00f3litos secund\u00e1rios oriundos de subst\u00e2ncias liqu\u00eanicas t\u00eam atra\u00eddo a \n\naten\u00e7\u00e3o de v\u00e1rios pesquisadores, por mais de 100 anos (Lawrey, 1986). Dentre as \n\n20.000 esp\u00e9cies de l\u00edquens conhecidas, apenas uma pequena parcela tem sido analizada \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\ne identificada como possuidora de componentes secund\u00e1rios biologicamente ativos \n\n(Romagni et al., 2000). Atualmente, muitos liquen\u00f3logos assumem que \u00e1cidos \n\nliqu\u00eanicos, isto \u00e9, \u00e0queles componentes secund\u00e1rios insol\u00faveis em \u00e1gua, apresentam \n\nv\u00e1rias fun\u00e7\u00f5es biol\u00f3gicas na natureza, embora o seu mecanismo de a\u00e7\u00e3o n\u00e3o tenha sido \n\ncompletamente elucidado (Rundel, 1978).  \n\n  As subst\u00e2ncias liqu\u00eanicas s\u00e3o eficientes contra bact\u00e9rias e fungos, impedem o \n\nb\u00e9m que os componentes fen\u00f3licos produzem altera\u00e7\u00f5es \n\nhemol\u00ed\n\n tempos atuais, as subst\u00e2ncias liqu\u00eanicas t\u00eam apresentado uma importante \n\ns \n\n.3.2. \u00c1cido Fumarprotocetr\u00e1rico \n\nlar (C22H16O12) \n\n?-orcinol, \u00e9 um \u00e9ster arom\u00e1tico \n\ncontendo o grupo carbox\u00edlico em seu anel terminal, ou seja, um \u00e1cido carbox\u00edlico \n\ninsaturado vin\u00edlico (Figura 7) (Edwards et al., 2003).  \n\ndesenvolvimento de tumores e c\u00e9lulas cancerosas, al\u00e9m de possu\u00edrem atividades \n\nfarmacol\u00f3gica e antigerminativa, dentre outras. De fato, subst\u00e2ncias liqu\u00eanicas de \n\nnatureza fen\u00f3lica t\u00eam apresentado a\u00e7\u00e3o comprovada contra tumores e c\u00e9lulas cancerosas \n\n(Nascimento et al., 1994). Baseando-se neste dado, pode-se afirmar que h\u00e1 estudos \n\nindicativos na possibilidade de utiliza\u00e7\u00e3o de uma base de sulfato de zinco associada ao \n\nmetab\u00f3lito secund\u00e1rio, \u00e1cido \u00fasnico, como terapia adjuvante do tratamento cir\u00fargico da \n\nles\u00e3o c\u00e9rvico-vaginal causada pelo Papiloma V\u00edrus Humano (HPV) (Scirpa et al., \n\n1999). \n\nPostula-se tam\n\nticas e d\u00e9rmicas, ou seja, danos nos constituintes de membrana dos eritr\u00f3citos e \n\nprodu\u00e7\u00e3o de dermatites de contato. Esta atividade \u00e9 decorrente da presen\u00e7a de \n\nal\u00e9rgenos, tais como deps\u00eddeos, depsidonas e derivatos do \u00e1cido \u00fasnico (Hidalgo et al., \n\n1993). \n\n Em\n\nfun\u00e7\u00e3o em t\u00e9cnicas de biomonitoramento, ou seja, em mapeamentos dos efeitos da \n\npolui\u00e7\u00e3o em \u00e1reas amplas. O ac\u00famulo de poluentes no talo poder\u00e1 mostrar o padr\u00e3o de \n\ndistribui\u00e7\u00e3o de cada poluente e o perfil das condi\u00e7\u00f5es naturais (Caviglia et al., 2001). \n\n De acordo com Yoshimura (1993), as principais fun\u00e7\u00f5es naturais dos l\u00edquen\n\nn\u00e3o foram ainda completamente compreendidas, apesar de terem sido detectadas v\u00e1rias \n\natividades biol\u00f3gicas, tais como: largo espectro de defesa contra v\u00edrus, bact\u00e9rias, \n\nparasitas, predadores e contra fatores de estresse ambiental (ex.: raios ultra-violeta) \n\n(Cocchietto et al., 2002). \n\n \n\n1\n\n1.3.2.1. Estrutura Qu\u00edmica Molecu\n\nO \u00e1cido fumarprotocetr\u00e1rico, uma depsidona \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\nCH H C\nO C\n\nO\nCH\n\nOH\n\n \n\nica do \u00e1cido fumarprotocetr\u00e1rico (Edwards \n\n1.3.2.2. Caracter\u00edsticas F\u00edsico-Qu\u00edmicas \n\nHO\n\nOHC\n\nCOO COOH\n\nCH3O\n\nFigura. 7. Estrutura qu\u00edm et al., 2003). \n\n \n\n \n\nO \u00e1cido fumarprotocetr\u00e1rico apresenta-se como cristais em forma de pequenas \n\nC e massa molecular de 472,37. Apresenta \n\nma limitada solubilidade na maioria dos solventes org\u00e2nicos, sendo sol\u00favel em acetona \n\nhidrata\n\nC\n\n1.3.2.3. Ocorr\u00eancia \n\n \n\nO \u00e1cido fumarprotocetr\u00e1rico constitui um metab\u00f3lito secund\u00e1rio de l\u00edquens.  A \n\nonfirmada pela utiliza\u00e7\u00e3o de c\u00e9lulas de Cladonia verticillaris \n\nobilizadas em alginato (Fontaniella et al., 2000). Dados sugerem que c\u00e9lulas \n\nimobili\n\nyma, \n\nsimilar\n\n3 2\nCH COOH\n\nagulhas, com ponto de fus\u00e3o de 250-260\u00b0\n\nu\n\nda (80~90%) e titulado como um \u00e1cido dib\u00e1sico (Asahina &amp; Shibata, 1954).  \n\nSegundo Asahina &amp; Shibata (1954), a equa\u00e7\u00e3o de hidr\u00f3lise do \u00e1cido \n\nfumarprotocetr\u00e1rico \u00e9 descrita como tal: \n\n \n\n22H16O12 + H2O = 2 C4H4O4 (\u00e1cido fum\u00e1rico) + C18H14O9 (\u00e1cido protocetr\u00e1rico) \n\n \n\nsua bioss\u00edntese foi c\n\nim\n\nzadas representam a melhor maneira para a produ\u00e7\u00e3o de metab\u00f3litos liqu\u00eanicos, \n\ntais como, os \u00e1cidos ev\u00e9rnico, \u00fasnico e fumarprotocetr\u00e1rico (Blanco et al., 2002).  \n\nEsp\u00e9cies de Cladonia (ex.: Cladonia imperialis, C. crinita e C. verticillaris) \n\nest\u00e3o entre as mais conhecidas Cladoniaceae nos tr\u00f3picos da Am\u00e9rica Latina (Stocker-\n\nWorgotter, 2001). Uma nova esp\u00e9cie encontrada na Calif\u00f3rnia, Cladonia lacr\n\n \u00e0s outras esp\u00e9cies da Cladonia, tamb\u00e9m \u00e9 caracterizada pela presen\u00e7a do \u00e1cido \n\nfumarprotocetr\u00e1rico (Hammer, 1991). Observou-se tamb\u00e9m a presen\u00e7a consider\u00e1vel \n\ndeste \u00e1cido em amostras russas de Parmelia stygia e na medula da Cladonia pyxidata \n\n(Herbacher et al., 1995). Enquanto que, na Cladonia verticillaris (Figura 8) o \u00e1cido \n\nfumarprotocetr\u00e1rico \u00e9 transportado da medula para o c\u00f3rtex, em resposta a uma \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nrehidrata\u00e7\u00e3o, pois muitas esp\u00e9cies de l\u00edquens acumulam-se no c\u00f3rtex por est\u00edmulo de \n\nluz (Mateos et al., 1993).  \n\n \n\nFigura. 8. Talo liqu\u00eanico da Cladonia verticillaris. \n\n(http;//.matisse.chem.uniroma1.it/ apol) \n\n  \n\nL\u00edquens fen\u00f3 nteparo protetor no \n\nc\u00f3rtex liqu\u00eanico que fil protegem os pigmentos \n\nfotosint\u00e9ticos nas c\u00e9lulas fotobi\u00f3ticas. Afirma-se que a ocorr\u00eancia natural dos l\u00edquens \n\nCladon\n\nnico, um ?-metileno-?-lactona e o \u00e1cido \n\nfumarprotocetr\u00e1rico, uma depsidona ?-orcinol s\u00e3o considerados os principais \n\nmetab\u00f3litos secund\u00e1rios biologicamente ativos da esp\u00e9cie de l\u00edquens Cetraria islandica \n\n(musgo\n\nlicos t\u00eam sido reportados por formarem um a\n\ntra a radia\u00e7\u00e3o e, por meio disso, \n\nia verticillaris, em regi\u00f5es ensolaradas e protegidas da luz, implica mudan\u00e7as no \n\nconte\u00fado do pigmento. Portanto, l\u00edquens que crescem em localiza\u00e7\u00f5es ensolaradas \n\ncont\u00eam mais carboxilato metil ?-orcinol, orcinol e \u00e1cido fumarprotocetr\u00e1rico do que \n\n\u00e0queles encontrados em regi\u00f5es de baixa intensidade de luz (Legaz et al., 1986).  \n\n \n\n1.3.2.4. Aplica\u00e7\u00f5es Biol\u00f3gicas \n\n1.3.2.4.1. Atividade Antibacteriana \n\n\u00c1cido protoliquester\u00ed\n\n irland\u00eas). A atividade antibacteriana tem sido atribu\u00edda tanto ao \u00e1cido \n\nprotoliquester\u00ednico quanto ao \u00e1cido fumarprotocetr\u00e1rico (Gudj\u00f3nsd\u00f3ttir &amp; Ing\u00f3lfsd\u00f3ttir, \n\n1997). Embora que, segundo Bustinza (1951), o \u00e1cido fumarprotocetr\u00e1rico n\u00e3o tenha \n\napresentado atividade antibacteriana contra E. coli e S. aureus.  \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\n1.3.2.4.2. Atividade Antimicobacteriana \n\n \n\nL\u00edquens v\u00eam sendo utilizados com finalidades medicinais h\u00e1 d\u00e9cadas e alguns \n\no tratamento da tuberculose pulmonar, tais \n\nomo as esp\u00e9cies de Cetraria islandica (musgo irland\u00eas), Lobaria pulmonaria e \n\nCladon\n\n na aplica\u00e7\u00e3o das cepas M. tuberculosis multif\u00e1rmaco-\n\nresisten\n\nSegundo Lima et al., (1990) baseando-se em dados referentes \u00e0 atividade \n\nstudos foram iniciados com extratos de Cladoniaceae ocorrentes em tabuleiros \n\nento (CI50) inferior a \n\n \u00b5g/\n\no a \n\na\u00e7\u00e3o sobre o bloqueio da s\u00edntese de prostaglandinas. \n\nt\u00eam sido requisitados por serem efetivos n\n\nc\n\nia (Vartia, 1973). \n\nDiversos componentes liqu\u00eanicos apresentam atividade contra esp\u00e9cies de \n\nMycobacterium e organismos Gram-positivos. Deste modo, apesar das in\u00fameras \n\ndificuldades encontradas\n\ntes, faz-se necess\u00e1rio a constante busca por novos agentes antituberculost\u00e1ticos, \n\nincluindo, a re-investiga\u00e7\u00e3o de v\u00e1rios metab\u00f3litos liqu\u00eanicos com respectiva atividade \n\nantimicobacteriana (Gangadharam, 1993). Em decorr\u00eancia da escassa solubilidade em \n\n\u00e1gua e a efic\u00e1cia reduzida comparada aos v\u00e1rios antibi\u00f3ticos de outras fontes, os \n\ncomponentes liqu\u00eanicos n\u00e3o v\u00eam sendo usados como potentes agentes antimicrobianos \n\n(Ing\u00f3lfsd\u00f3ttir et al., 1998). \n\n \n\n1.3.2.4.3. Atividades Citot\u00f3xica e Antitumoral \n\n \n\n \n\nantitumoral dos polissacar\u00eddeos e dos fen\u00f3is, obtidos de diferentes esp\u00e9cies de l\u00edquens, \n\ne\n\narenosos do Estado da Para\u00edba, Brasil.   \n\n Em rela\u00e7\u00e3o \u00e0 atividade citot\u00f3xica, Cladonia dendroides foi a esp\u00e9cie cujos \n\nextratos contendo atranorina, \u00e1cido protocetr\u00e1rico e \u00e1cido fumarprotocetr\u00e1rico, na forma \n\net\u00e9rea, apresentou uma concentra\u00e7\u00e3o inibit\u00f3ria de 50% do crescim\n\n50 mL contra as c\u00e9lulas MDA-MB231. Isto permite supor que o princ\u00edpio ativo \n\ndeste extrato \u00e9 a atranorina, com a prov\u00e1vel associa\u00e7\u00e3o ao complexo do \u00e1cido \n\nfumarprotocetr\u00e1rico. Quando o extrato bruto apresenta IC50 inferior a 50 \u00b5g/mL, o \n\nresultado \u00e9 considerado satisfat\u00f3rio para o prosseguimento de estudos antineopl\u00e1sicos, \n\nou seja, menor toxicidade ser\u00e1 ocasionada ao organismo (Nascimento et al., 1994).  \n\n Segundo Oliveira (2003), o \u00e1cido fumarprotocetr\u00e1rico isolado da Cladonia \n\nverticillaris (Raddi. Fr.) exibe atividades edematog\u00eanica e antipir\u00e9tica frente ao modelo \n\nexperimental de inflama\u00e7\u00e3o aguda (edema de pata induzido por zimosan), sugerind\n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\n1.4. MECANISMO DE A\u00c7\u00c3O PROPOSTO DO \u00c1CIDO \n\nFUMARPROTOCETR\u00c1RICO \n\n \n\nApesar do conhecimento sobre o mecanismo de inibi\u00e7\u00e3o dos \u00e1cidos liqu\u00eanicos \n\n\u00e9tico. Estes \u00e1cidos tais como: \u00fasnico, vulp\u00ednico e a \n\ntranorina influenciam na mitoc\u00f4ndria e no metabolismo energ\u00e9tico, devido as suas \n\ncaracte\n\nem v\u00e1rios organismos, estudos recentes t\u00eam sugerido que alguns \u00e1cidos liqu\u00eanicos \n\ninterferem no metabolismo energ\n\na\n\nr\u00edsticas f\u00edsico-qu\u00edmicas, lipofilicidade e ioniza\u00e7\u00e3o e por exibirem caracter\u00edsticas \n\ndo 2,4-dinitrofenol (DNP), um cl\u00e1ssico desacoplador da fosforila\u00e7\u00e3o oxidativa (Abo-\n\nKhatwa et al., 1996). Segundo Vavasseur (1991), a atividade antimicrobiana destes \n\nl\u00edquens est\u00e1 associada ao desacoplamento da fosforila\u00e7\u00e3o oxidativa nas c\u00e9lulas \n\nmicrobianas. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n2. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS \n\n \n\nABBAS, A. K., LICHTMAN, A. H., POBER, J. S. Imunologia Celular &amp; Molecular, 4a ed. Ed. \n\nRevinter, Rio de Janeiro-RJ, 2003. \n\nABBAS, A. K., LICHTMAN, A. H., POBER, J. S. Imunologia Celular &amp; Molecular, 3a ed. Ed. \n\nRevinter, Rio de Janeiro-RJ, 2000. \n\nABO-KHATWA, A. N., AL-ROBAI,  A. A. AL-JAWHARI, D. A. Lichen acids as uncouplers \n\nof oxidative phosphorylation of mouse-liver mitochondria. Natural Toxins, 4, 96-102, 1996.  \n\nALBERTS, B., BRAY, D., LEWIS, J., RAFF, M., ROBERTS, K. D. WATSON, J. Biologia \n\nMolecular da C\u00e9lula, 3a ed. Ed. Artmed, Porto Alegre-RS, 1997. \n\nAMIJI, M. M. &amp; PARK, K. Prevention of protein adsorption and platelet adhesion on the \n\nsurfaces by PEO/PPO/PEO triblock copolymers. Biomaterials,  202, 1-10, 2000. \n\nAMMOURY, N. Etude Physico-chimique et Biologique de Vecteurs Collo\u00efdaux V\u00e9siculaires d\u2019 \n\nIndom\u00e9tacine Acide polylactique; doctoral thesis; Universit\u00e9 Paris Sud, mention Sciences \n\nPharmaceutiques 167, 1990.  \n\nANSEL, H. C., POPOVICH, N. G. ALLEN JR., L. V. Farmacot\u00e9cnica: Formas Farmac\u00eauticas \n\n&amp; Sistemas de Libera\u00e7\u00e3o de F\u00e1rmacos, 6\u00aa ed. Editorial Premier, S\u00e3o Paulo-SP, 2000. \n\nASAHINA, Y. &amp; SHIBATA, S. Chemistry of Lichen Substances. Japan Society for the \n\nPromotion of Science, Tokyo, Japan, 1954. \n\nBARRAT, G. M. Therapeutic applications of colloidal drug carriers. PSTT, 3(5), 163-171, \n\n2000.  \n\nBENITA, S.  Microencapsulation \u2013 Methods and Industrial Applications. Benita, S., Ed.; \n\nMarcel Dekker, New York, 1996. \n\nBERTON, M., BENIMETSKAYA, L., ALL\u00c9MANN, E., STEIN, C. A. GURNY, R. \n\nUptake of oligonucleotide-loaded nanoparticle in prostatic cancer cells and their \n\nintracellular localization. European Journal of Pharmaceutics and \n\nBiopharmaceutics, 47, 119-123, 1999. \n\nBLANCO, Y., BLANCH, M., FONTANIELLA, B., LEGAZ, M. E., MILLANES, A. M., \n\nPEREIRA, E. C., VICENTE, C. Bioproduction of lichen phenolics by immobilized lichen cells \n\nwith emphasis on the role of epiphytic bacteria. Journal of the Hattori Botanical Laboratory, \n\n92, 245-260, 2002. \n\nBOSE, L. &amp; BANERJEE, N. C. Studies on antibiotics from indian lichens part I. isolation of \n\nantibiotic compounds from Parmelia tinctorum. Bulletim of Botanic Society Bengal, 30, 125-\n\n127, 1976. \n\nBOUCHEMAL, K., BRIAN\u00c7ON, S., PERRIER, E., FESSI, H., BONNET, I. ZYDOWICZ, N. \n\nSynthesis and characterization of polyurethane and poly(etherurethane) nanocapules using a \n\nnew technique of interfacial polycondensation combined to spontaneous emulsification. \n\nInternational Journal of  Pharmaceutics, 269, 89-100, 2004. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nBRANNON-PEPPAS, L. Polymers in Controlled Drug Delivery. Dispon\u00edvel em &lt;http: // \n\nwww.devicelink.com/mpb/archive/97/11/003.html>. Acesso em novembro de 2003.  \n\nBRIGGER, I., DUBERNET, C. COUVREUR, P. Nanoparticles in cancer therapy and \n\ndiagnosis. Advanced Drug Delivery Reviews, 54, 631-651, 2002. \n\nBUSTINZA, F. Anticacterial substances from lichens. Endeavour, 10(38), 95-99, 1951. \n\nCALVO, P., VILA-JATO, J. L. ALONSO, M. J. Evaluation of cationic polymer-coated \n\nnanocapsules as ocular drug carriers. Journal of Pharmaceutics Science, 85: 530-6, 1996. \n\nCAUCHETIER, E., DENIAU, M., FESSI, H., ASTIER, A. PAUL, M. Atovaquone-loaded \n\nnanocapsules: influence of the nature of the polymer in vitro characteristics. International \n\nJournal of Pharmaceutics, 250, 273-281, 2003. \n\nCAVIGLIA, A. M., NICORA, P., GIORDANI, P., BRUNIALTI, G. MODENESI, P. Oxidative \n\nstress and usnic acid content in Parmelia caperata and Parmelia soredians (Lichenes). IL \n\nFarmaco, 56, 379-382, 2001. \n\nCOCCHIETTO, M., SKERT, N., NIMIS, L. P. A rewiew on usnic acid, an interesting natural \n\ncompound. Naturwissenschaften, 89, 137-146, 2002. \n\nCOLOMBO, A. P., BRIAN\u00c7ON, S., LIETO, J. FESSI, H. Project, design, and use of a pilot \n\nplant for nanocapsule poduction. Drug Development and Industrial Pharmacy, 27 (10), \n\n1063-1072, 2001. \n\nCOOPER, G. M. A c\u00e9lula: uma abordagem celular, 2a ed. Ed. Artmed, Porto Alegre-RS, 2001. \n\nCOUVREUR, P. Vecteurs nanoparticulaires de m\u00e9dicaments. In: BURI, P. et al.. Formes \n\npharmaceutiques nouvelles. Aspects technologiques, biopharmaceutiques et medicals. 2 ed. \n\nParis: Lavosier, cap. 14, p. 577-611, 1985. \n\nCOUVREUR, P., KANTE, B., GRISLAIN, L., ROLAND, M. SPEISER, P. Toxicity of \n\npolyalkylcyanoacrylate nanoparticles. II: Doxorubicin loaded nanoparticles. Journal of  \n\nPharmaceutics Science, 71, 790-2, 1982. \n\nCULBERSON, C. F. &amp; ELIX, J. A. Lichen Substances. Methods in Plant Biochemistry, v. 1, \n\n1972. \n\nD\u2019 CRUZ, O. J. &amp; UCKUM, F. M. Gel-microemulsions as vaginal spermicides and intravaginal \n\ndrug delivery vehicles, Contraception, 64, 113-123, 2001. \n\nEDWARDS, H. G. M., NEWTON, E. M., WYNN-WILLIAMS, D. Molecular structural studies \n\nof lichens substances II: atranorin, gyrophoric acid, fumarprotocetraric acid, rhizocarpic acid, \n\ncalycin, pulvinic dilactone and usnic acid. Journal of Molecular Structure, 1-11, 2003. \n\nFAVARO, O. C. N., OLIVEIRA, M. M., ROSSINI, A., KAMARA, C. R., PINTO, A. V. \n\nPINTO, M. C. Sele\u00e7\u00e3o por meio de C\u00e9lulas KB de subst\u00e2ncias e extratos potencialmente ativos \n\nem quimioterapia do c\u00e2ncer. Anais da Academia Brasileira de Ci\u00eancias. Rio de Janeiro. 62 (3) \n\n271-224, 1990. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nFESSI, H.; PUISIEUX, F., DEVISSAGUET, J. P., AMMOURY, N. E. BENITA, S. N. \n\nNanocapsules formation by interfacial polymer deposition following solvent displacement. \n\nInternational Journal of Pharmaceutics, 55, 1-4, 1989. \n\nFONTANIELLA, B., LEGAZ, M. E., PEREIRA, E. C., SEBASTIAN, B. VICENTE, C. \n\nRequirements to produce fumarprotocetraric acid using alginate-immobilized cells of Cladonia \n\nverticillaris. Biotechnology Letters, 22(10), 813-817, 2000.  \n\nGALLARDO, M. M., ROBLOT-TREUPEL, L., MAHUTEAU, J., GENIN, I., COUVREUR, \n\nP., PLAT, M. PUISIEUX, F. Nanocapsules et nanosph\u00e8res d\u2019alkyl-cyanoacrylatye, interactions \n\nprincipe actif/polym\u00e8re. Proc. APGI, 5th International Conference on Pharmaceutical \n\nTechnology, pp.36-45, Paris 1989. \n\nGANGADHARAM, P. R. J. Drug Resistance in Tuberculosis, In: Reichman, L. B., Hershfield, \n\nE. S. (Eds.), Tuberculosis, A Comprehensive International Approach. Marcel Dekker, New \n\nYork, pp. 293-328, 1993. \n\nGAUR, U., SAHOO, S. K., DE, T. K., GHOSH, P. C., MAITRA, A. GHOSH, P. K. \n\nBiodistribuiton of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial \n\nsystem. International Journal of Pharmaceutics, 202, 1-10, 2000. \n\nGIBAUD, S.; ROUSSEAU, C.; WEINGARTER, C.; FAVIER, R.; DOUAY, L.; ANDREUX, J. \n\nP. COUVREUR, P.  Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony \n\nstimulating factor (G-CSF). Journal of Controlled Release, 52, 131-139, 1998. \n\nGREF, R., COUVREUR, P., BARRAT, G. MYSIAKINE, E. Surface-engineered nanoparticles \n\nfor ligand coupling. Biomaterials, 24, 4529-4537, 2003.  \n\nGRIFFITHS, A. J. F., MILLER, J. H., SUZUKI, D. T., LEWONTIN, R. C. GELBART, W. M. \n\nIntrodu\u00e7\u00e3o \u00e0 Gen\u00e9tica, 6 a ed. Ed. Guanabara Koogan S/A, Rio de Janeiro-RJ, 1998. \n\nGRISLAIN, L., COUVREUR, P. LENAERTS, V. Pharmacokinetic and distribuiton of a \n\nbiodegradable drug-carrier. International Journal of Pharmaceutics, 15, 355-45, 1983. \n\nGRIT, M., DE SMIDT, J. H., STRUIJKE. CROMMELIN, D. J. A. Hydrolysis of \n\nphosphatidylcholine in aqueous liposome dispersions. International Journal of \n\nPharmaceutics, 50, 1-6, 1989.  \n\nGUDJ\u00d3NSD\u00d3TTIR, G. A. &amp; ING\u00d3LFSD\u00d3TTIR. K. Quantitative determination of \n\nprotolichesterinic and fumarprotocetraric acids in Cetraria islandica by high-performance liquid \n\nchomatography. Journal of Chomatography A, 757, 303-306, 1997. \n\nGUINEBRETI\u00c8RE, S., BRIANON, S., FESSI, H., TEODORESCU, V.S. BLANCHIN, M.G. \n\nNanocapsules of biodegradable polymers: preparation and characterizatin by direct high \n\nresolution electron microscopy. Materials Science &amp; Engineering, 21, 137-142, 2002.  \n\nGUYTON, A.C. &amp; HALL, J.E. Tratado de Fisiologia M\u00e9dica, 10a ed. Ed. Guanabara Koogan \n\nS/A, Rio de Janeiro-RJ, 2002. \n\nHAMMER, S. A preliminary synopsis of the species of Cladonia in California and adjacent \n\noregon. Mycotaxon, 40, 169-197, 1991. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nHANS, M. L. &amp; LOWMAN, A. M. Biodegradable nanoparticles for drug delivery and targeting. \n\nCurrent Opinion in Solid State &amp; Materials Science, 1, 0-0, 2002.    \n\nHARDMAN, G. J., LIMBIRD, E. L. GOODMAN &amp; GILMAN \u2013 As Bases \n\nFamacol\u00f3gicas da Terap\u00eautica. 9 ed. Mc Graw Hill, 1996. \n\nHENRY, J. B. Diagn\u00f3sticos Cl\u00ednicos e Tratamento por M\u00e9todos Laboratoriais, 19\u00aa ed. Ed. \n\nMande, S\u00e3o Paulo-SP, 1999. \n\nHERBACHER, S., GIEZ, I., EMBACHER, G., FIEDLER, K., MAX, W., TRAWOGER, A., \n\nTURK, R., LANGE, O. L. PROKSCH, P. Sequestration of lichen compounds by lichen-feeding \n\nmembers of the Arctiidae (Lepidoptera). Journal of Chemical Ecology, 21(12), 2079-2089, \n\n1995. \n\nHIDALGO, M. E., FERN\u00c1NDEZ, E. QUILHOT, W. Photohemolytic activity of lichen \n\nmetabolites. Journal of Photochemistry and Photobiololy B: Biology, 21, 37-40, 1993. \n\nING\u00d3LFSD\u00d3TTIR, K., CHUNG, G. A. C., SK\u00daLASON, V. G., GISSURARSON, S. R.  \n\nVILHJ\u00c1LMUR, M. Antimycobacterial activity of lichen metabolites in vitro. European \n\nJournal of Pharmaceutical Sciences, 6, 141-144, 1998.   \n\nJALIL, R. &amp; NIXON,  J. R. Biodegradable poly (lactic acid) and poly (lactide-co-glycolide) \n\nmicrocapsules: problems associated with preparative and release properties. Journal of \n\nMicroencapsulation, 297-325, 1990.   \n\nJULIENNE, M. C., ALONSO, M. J., GOMEZ AMONZA, J. L. BENOIT, J. P.  Preparation of \n\npoly (DL-lactide-glycolide) nanoparticles of controlled particle size distribuiton: application of \n\nexperimental designs. Drug Development and Industrial Pharmacy, 18, 1063-1077, \n\n1992. \n\nKIM, I. &amp; KIM, K. Development of polymeric nanoparticulate drug delivery systems: \n\nevaluation of nanoparticles based on biotinylated poly (ethylene glycol) with sugar moity. \n\nInternational Journal of Pharmaceutics, 257, 195-203, 2003. \n\nKREUTER, J. Nanoparticulate systems for brain delivery of drugs. Advanced Drug Delivery \n\nReviews, 47, 65-81, 2001. \n\nLACHMAN, L., LIBERMAN, H. A. KANING, J. L. The Theory and Practice of Industrial \n\nPharmacy. v. II. Funda\u00e7\u00e3o Calouste Gulbenkian, Lisboa, 2001. \n\nLAMBERT, G., FATTAL, E. COUVREUR, P. Nanoparticulate systems for the delivery of \n\nantisense oligonucleotides. Advanced Drug Delivery Reviews, 47,  99-112, 2001.  \n\nLAVERMAN, P., CARSTENS, M. G., STORM, G. MOGHIMI, S. M. Recognition and \n\nclearance of methoxypoly (ethyleneglycol) 200-grafted liposomes by macrophages with \n\nenhanced phagocytic capacity. Implications in experimental and clinical oncology. Biochimica \n\net Biophysica Acta, 1526, 227-229, 2001.  \n\nLAWREY, J. D.  Biological role of lichens substances. The Bryologist, 89 (2), 111-122, 1986. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nLEE, J., PARK, K., LIM, S., LEE, M. KIM, C. Microemulsion formulation of clonixic acid: \n\nsolubility enhancement and pain reduction. Journal of Pharmacy and Pharmacology, 54, 43-\n\n49, 2002. \n\nLEGAZ, M. E., VICENTE, C., GALLO, M. XAVIER-FILHO, L. Lichen phenols from \n\nCladonia dendroides thalli. Lichen Physiology and Biochemistry, 2, 13-21, 1986. \n\nLEMOINE, D. &amp; PREAT, V. Polymeric nanoparticles as the delivery system for influenza virus \n\nglycoproteins. Journal of Controlled Release, 54, 15-27, 1998. \n\nLI, Y., PEI, Y., ZHOU, Z., ZHANG, X., GU, Z., DING, J., ZHOU, J. GAO, X. PEGylated \n\npolycyanoacrylate nanoparticles as tumor necrosis factor-? carriers. Journal of Controlled \n\nRelease, 71, 287-296, 2001.    \n\nLIMA, R. C., NASCIMENTO, S. C., PEREIRA, E. C. CAMPOS\u2013TAKAKI, G. M. Atividade \n\ncitot\u00f3xica e antitumoral de extratos liqu\u00eanicos. Bol. Soc. Brot., 63, 339-348, 1990.  \n\nMAGENHEIM, B. &amp; BENITA, S. Nanoparticle characterization: a comprehensive \n\nphysicochemical approach. STP Pharma Sciences, 1,  221-241, 1991.  \n\nMATEOS, J. L., PEDROA, M. M., MOLINA, M. D., PEREIRA, E. C., VICENTE, C. LEGAZ, \n\nM. E. Involvement of Phytochrome-mediated cyclic-AMP in the synthesis and deposition of \n\nfumarprotocetraric acid on cortical hyphae of Cladonia verticillaris. Plant Physiology and \n\nBiochemistry, 31(5), 667-674, 1993. \n\nMINIST\u00c9RIO DA SA\u00daDE. INSTITUTO NACIONAL DE C\u00c2NCER. COORDENA\u00c7\u00c3O DE \n\nPROGRAMAS DE CONTROLE DE C\u00c2NCER-PRO-ONCO. \u201cO Problema do C\u00e2ncer no \n\nBrasil\u201d. 4\u00aa ed. Rio de Janeiro, 2003. \n\nMITRA, S., GAUR, U., GHOSH, P. C. MAITRA, A. N. Tumor targeted delivery of \n\nencapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. Journal \n\nControlled Release, 74, 317-323, 2001. \n\nMOGHIMI, S. M. &amp; HUNTER, C. Poloxamers and poloxamines in nanoparticle engineering \n\nand experimental medicine. Tibtech October, 18, 2000. \n\nMONTENEGRO, M.R. &amp; FRANCO, M. Patologia Processos Gerais, 4a ed., Ed. Atheneu, S\u00e3o \n\nPaulo-SP, 1999. \n\nMU, L. &amp; FENG, S. S. A novel controlled release formulation for the anticancer drug paclitaxel \n\n(Taxol?): PLGA nanoparticles containing vitamin E TPGS. Journal of Controlled Release, 86, \n\n33-48, 2003.  \n\nMURRAD, A. M. &amp; KATZ, A. Oncologia: Bases Cl\u00ednicas do Tratamento. Ed. Guanabara \n\nKoogan, Rio de Janeiro, 1996. \n\nNASCIMENTO, S. C., PEREIRA, E. C., OLIVEIRA, A. F. M., SILVA, N. H., BOITARD, M. \n\nBERIEL, H. Screenig de Atividade Citot\u00f3xica de Extratos Liqu\u00eanicos: Cladoniaceae. Acta \n\nBot\u00e2nica Brasileira, 8 (1), 1994. \n\nNELSON, D. L. &amp; COX, M. M. Lehninger. Princ\u00edpios da Bioqu\u00edmica, 3a ed. Ed. Sarvier, S\u00e3o \n\nPaulo-SP, 2000. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nOLIVEIRA, M. S. Atividade antinociceptiva, antipir\u00e9tica e antiinflamat\u00f3ria do extrato \n\nbruto e do \u00e1cido fumarprotocetr\u00e1rico isolado de Cladonia verticillaris (L\u00edquen), 2003. 82 p. \n\nTese de Mestrado, Universidade Federal de Pernambuco, Brasil. \n\nPARK, K. &amp; KIM, C. Preparation and evaluation of flurbiprofen-loaded microemulsion for \n\nparenteral delivery. International Journal of Pharmaceutics, 181, 173-179, 1999. \n\nPRISTA, N., ALVES, A.C. MORGADO, R. Tecnologia Farmac\u00eautica, 4\u00aa ed. v. III. Funda\u00e7\u00e3o \n\nCalouste Gulbenkian, Lisboa, 1995. \n\nREYNOLDS, A. R., MOGHIMI, S. M. HODIVALA-DILKE, K. Nanoparticle-mediated gene \n\ndelivery to tumour neovasculature. Trends in Molecular Medicine,  9, 1, 2003.  \n\nROBBINS, S. L, COTRAN, R. S., KUMAR, V. COLLINS, T. Patologia Estrutural e \n\nFuncional, 6 a ed. Ed. Guanabara Koogan, Rio de Janeiro-RJ, 2001. \n\nRODRIGUES, O. G. Estudo in vitro para avalia\u00e7\u00e3o das altera\u00e7\u00f5es morfol\u00f3gicas das c\u00e9lulas \n\nHep2, NCIH-292 e TVT canino produzidas por imunoparvum e in vivo para verifica\u00e7\u00e3o \n\ndos seus efeitos terap\u00eauticos.,2001.127p. Tese (Doutorado), Universidade Federal de \n\nPernambuco, Brasil. \n\nROMAGNI, J. G., MEAZZA, G., NANAYAKKARA, N. P. DAYAN, F. E. The phytotoxic \n\nlichen metabolite, usnic acid, is a potent inhibitor of plant ?-hydroxyphenylpyruvate \n\ndioxygenase. FEBS Letters, 480, 301-305, 2000. \n\nRUNDELL, P. W. The ecological role of secundary lichen substances. Biochemical \n\nSystematics and Ecology, 6, 157-170, 1978. \n\nSANTOS, N. P. Nanoc\u00e1psulas de PLGA contendo \u00e1cido \u00fasnico de Cladonia substellata com \n\npotencial a\u00e7\u00e3o antitumoral, 2003. 124 p. Tese (Doutorado em Ci\u00eancias Biol\u00f3gicas), \n\nUniversidade Federal de Pernambuco, Brasil. \n\nSCIRPA, P., SCAMBIA, G., MASCIULLO, V., BATTAGLIA, F., FOTI, E., LOPEZ, R., \n\nVILLA, P., MALECORE, M. MANCUSO, S. Terapia adiuvante con un preparato a base di \n\nzinco solfato e acido usnico delle lesioni genitali da Human Papilloma V\u00edrus (HPV) dopo \n\ntrattamento chirurgico distruttivo. Minerva Ginecology, 51, 255-260, 1999. \n\nSILVA, P. Farmacologia, 6a ed. Ed. Guanabara Koogan S/A, Rio de Janeiro-RJ, 2002. \n\nSINGLA, A. K., GARG, A. AGGARWAL, D. Paclitaxel and its formulations. International \n\nJournal of Pharmaceutics, 235, 179-192, 2002.  \n\nSOMA, C. E., DUBERNET, C., BARRAT, G., BENITA, S. COUVREUR, P. Investigation of \n\nthe role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded \n\nnanoparticles on M2076 cells in vitro. Journal of Controlled Release, 68, 283-289, 2000.  \n\nSOPPIMATH, K. S., AMINABHAVI, T. M., KULKARNI, A. R. RUDZINSKI, W. E. \n\nBiodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled \n\nRelesase, 70, 1-20, 2001.   \n\nSPENCE, R. A. &amp; JOHNSTON, P. G. Oncologia. Ed. Guanabara Koogan, Rio de Janeiro-RJ,  \n\n2003. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nSTAINMESSE, S. Etude Gal\u00e9nique d\u2019u Nouveau Procede d\u2019Obtention de Vecteurs Collo\u00efdaux \n\nSubmicroniques \u00e1 Partir d\u2019une Prot\u00e9ine ou d\u2019un Polym\u00e8re Synth\u00e9tique; doctoral thesis; \n\nUniversit\u00e9 Paris Sud, mention Sciences Pharmaceutiques 129, 1990. \n\nSTITES, D. P., TERR, A. I. PARSLOW, T. G. Imunologia M\u00e9dica, 9\u00aaed. Ed. Guanabara \n\nKoogan, Rio de Janeiro-RJ, 1997. \n\nSTOCKER-WORGOTTER, E. Experimental studies of the lichen symbiosis: DNA-analyses, \n\ndifferentiation and secondary chemistry of selected mycobionts, artificial resynthesis of two-and \n\ntripartite symbioses. Symbiosis, 30(2-3), 207-227, 2001. \n\nSTONE, T. &amp; DARLINGTON, G. Pills, potions, poisons. How drugs work?. Oxford \u2013\n\nUniversity Press, 2000. \n\nTENJARLA, S. Microemulsions: an Overview and Pharmaceutical Applications.Critical \n\nRewiews TM in Therapeutic Drug Carrier Systems, 16 (5), 61-521, 1999. \n\nTROTTA, M., GASCO, M. R. MOREL, S. Release of drugs from oil-water microemulsions. \n\nJournal of Controlled Release, 10, 237-243, 1989. \n\nVARTIA, K.O. Antibiotics in lichens. In: Ahmadjian, V., Hale, M. E. (Eds.), The Lichens. \n\nAcademic Press, New York, pp. 547-561, 1973. \n\nVAUTHIER, C., DUBERNET, C., CHAUVIERRE, I., BRIGGER, P. COUVREUR, P. Drug \n\ndelivery to resistant tumors: the potential of poly (alkyl cyanoacrylate) nanoparticles. Journal \n\nof Controlled Release., 93, 151-160, 2003. \n\nVAVASSEUR, A., GAUTIER, H., THIBAUD, M. LASC\u00c8VE, G. Effects of usnic acid on the \n\noxygen exchange properties of mesophyll cell protoplasts from Commelina communis L. \n\nJournal of Plant Physiology, 139, 90-94, 1991. \n\nZAMBAUX, M. F., BONNEAUX, F., GREF, R., MAINCET, P., DELLACHERIE, E., \n\nALONSO, M. J., LABRUDE, P. VIGNERON, C. Influence of experimental parameters on the \n\ncharacteristics of poly (lactic acid) nanoparticles prepared by a double emulsion method. \n\nJournal of Controlled Release, 50, 31-40, 1998. \n\nYAMAMOTO, Y., KINOSHITA, Y., MATSUBARA, H., KINOSHITA, K., KOYAMA, K., \n\nTAKAHASHI, K., KURUKAWA, T. YOSHIMURA, I. Secreening of biological activities and \n\nisolation-active compounds from lichens. Recent Research and Development in \n\nPhytochemistry, 2, 1998. \nYOO, H. S., OH, J., LEE, K. H. PARK, T. G. In vitro and in vivo anti-tumor activities of \n\nnanoparticles based on doxorubicin\u2013PLGA conjugates. Journal of Controlled Release, 68, \n\n419-431, 2000.  \n\n \n\n \n\n \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n3. OBJETIVOS \n \n\n \n\n3.1. GERAL: \n\n \n\nDeterminar as atividades citot\u00f3xica, t\u00f3xica e antitumoral de um sistema \n\ncarreador de f\u00e1rmaco, nanoc\u00e1psulas de copol\u00edmero biodegrad\u00e1vel de \u00e1cido l\u00e1tico e \n\nglic\u00f3lico (PLGA), contendo o \u00e1cido fumarprotocetr\u00e1rico, extra\u00eddo de Cladonia \n\nverticilaris, visando uma poss\u00edvel aplica\u00e7\u00e3o anticancer\u00edgena e tuberculost\u00e1tica.  \n\n \n\n3.2. ESPEC\u00cdFICOS: \n\n \n\nEncapsular o \u00e1cido fumarprotocetr\u00e1rico em nanoc\u00e1psulas de copol\u00edmero de \u00e1cido \n\nl\u00e1tico e glic\u00f3lico (PLGA 50/50), utilizando o \u00f3leo de soja ou uma mistura de \n\nmicroemuls\u00e3o (O/A) e \u00f3leo de soja, como fase oleosa interna;  \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\n\u2022 \n\nDeterminar as caracter\u00edsticas f\u00edsico-qu\u00edmicas das nanoc\u00e1psulas, a fim de se \n\nestabelecer um perfil de estabilidade desse sistema carreador de f\u00e1rmaco; \n\nEstudar a cin\u00e9tica de libera\u00e7\u00e3o in vitro do \u00e1cido fumarprotocetr\u00e1rico a partir das \n\nnanoc\u00e1psulas; \n\nEstudar a citotoxicidade do \u00e1cido fumarprotocetr\u00e1rico, livre e encapsulado, frente \n\n\u00e0s c\u00e9lulas humanas de c\u00e2ncer de pulm\u00e3o (NCI-H 292) e c\u00e2ncer epiderm\u00f3ide de \n\nlaringe (HEp-2); \n\nDeterminar a toxicidade in vivo do \u00e1cido fumarprotocetr\u00e1rico, livre e encapsulado, \n\nem modelos animais murinos;  \n\nAnalisar a atividade antitumoral in vivo do \u00e1cido fumarprotocetr\u00e1rico, livre e \n\nencapsulado, frente ao Sarcoma 180, em camundongos. \n\n \n\n \n\n \n\n \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nARTIGO  \n\n \n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \nANTITUMOR ACTIVITY AND TOXICITY OF FUMARPROTOCETRARIC \n\nACID-LOADED NANOCAPSULES \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n \n\n \n\n \n\n \n\n \n\n \n\nTrabalho a ser submetido ao \n\n\u201cInternational Journal of Pharmaceutics\u201d \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\nAntitumor activity and toxicity of fumarprotocetraric acid-loaded \n\nnanocapsules \n\n \n \n\n Ana C. Simonettia,b, Noemia P. Santosa, Milena. S. Ferraz a, Daniele B. Cruza, Silene C. \n\nNascimentoc, Eug\u00eania C. Pereirac, Nic\u00e1cio H. Silvab, Nely K. Hondad, Nicodemos T. \n\nPontesa, E. S\u00f3crates T. Egitoe and  Nereide S. Santos-Magalh\u00e3esa,b ? \n\n \naLaborat\u00f3rio de Imunopatologia Keizo-Asami (LIKA) \n\nUniversidade Federal de Pernambuco (UFPE) \n\nAv. Prof. Moraes Rego, 1235, Cidade Universit\u00e1ria 50670-901 Recife-PE, Brasil \nbDepartamento de Bioqu\u00edmica, Centro de Ci\u00eancias Biol\u00f3gicas, UFPE \n\ncDepartamento de Antibi\u00f3ticos, Setor de Farmacologia, Laborat\u00f3rio de Cultura de \n\nC\u00e9lulas e Cancerologia Experimental, UFPE, Brasil \ndUniversidade Federal de Mato Grosso do Sul, Departamento de Qu\u00edmica, Laborat\u00f3rio \n\nde Produtos Naturais, UFMS, Brasil \neUniversidade Federal do Rio Grande do Norte, Laborat\u00f3rio de Sistemas Dispersos, \n\nUFRN, Brasil \n\n \n\nKeywords: Fumarprotocetraric acid; Nanocapsules; Microemulsions; Cytotoxicity; \n\nToxicity; Antitumor activity \n\n \n\n?Corresponding author \n\nDr. Nereide Stela Santos Magalh\u00e3es ( ) \n\nUniversidade Federal de Pernambuco (UFPE) \n\nGrupo de Sistemas de Libera\u00e7\u00e3o Controlada de Medicamentos \n\nLaborat\u00f3rio de Imunopatologia Keiso-Asami (LIKA) \n\nAv. Prof. Moraes Rego, 1235, Cidade Universit\u00e1ria \n\n50670-901, Recife, PE, Brazil \n\nTel: +55-081-32718587; fax: +55-081-32718485 \n\nE-mail: nssm@ufpe.br \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\nmailto:nssm@ufpe.br\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nAbstract \n\n \n\nNanoparticles are polymeric colloidal carriers used as drug delivery systems. \n\nOil-in-water microemulsions as a drug delivery system include improvement of drug \n\nsolubilization. The main purpose of this work is to investigate the citotoxicity, toxicity \n\nand antitumor activity of free and fumarprotocetraric acid (FPA), obtained from \n\nCladonia verticillaris, encapsulated into PLGA-nanocapsules.  \n\nResults showed that the efficiency of the fumarprotocetaric acid into PLGA-\n\nnanocapsules in different carries was 49.5% (FPA-NC) and 86.2% (FPA-NC/ME) \n\nrespectively. The viability of  NCI-H 292 and HEp-2 cells treated with FPA, NC and \n\nFPA-loaded nanocapsules was observed even at 50 \u00b5g.mL-1. In contrast, the NCI-H 292 \n\nand HEp-2 cells treaty with with o/w microemulsion (ME) or FPA-ME promoted a high \n\ncytotoxicity at 6.25 \u00b5g.mL-1, 25% and 35% cell viability, respectively. The treatment \n\nwith FPA encapsulated in NC/ME promoted pronounced injuries in liver and kidneys of \n\nanimals. However the antitumor activity promoted by free FPA, unloaded-nanocapsules \n\nand FPA-loaded nanocapsules evaluated on Sarcoma 180-bearing mice promoted 61.4% \n\nof tumor inhibition when compared with free FPA (58.9%) in relation to the control \n\ngroup. \n\nThe nanoencapsulation with microemulsion without Cremophor\u00ae can therefore \n\nbe considered as a potential alternative to improve solubilization of lichens metabolites, \n\nsuch as fumarprotocetraric acid.  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n1. Introduction \n\n \n\n  The key purpose of nanotechnology is the design of miniaturized drug carrier \n\nsystems to achieve suitable stability, improved absorption, controlled release, \n\nquantitative transfer and, therefore, the expected pharmacodynamic activity (Santos-\n\nMagalh\u00e3es et al., 2000). The potential of site specific delivery in optimizing drug \n\ntargeting has provided a tremendous advancement in handling new dosage forms such \n\nas nanoparticles, which are solid colloidal polymeric carriers in size range of 1-1,000 \n\nnm  (Gaur et al., 2000).  \n\nNanoparticles may act as a drug vehicle able to target tumor tissues or cells, to a \n\ncertain extent, while protecting the drug from a premature inactivation during its \n\ntransport. Thus, in order to deliver therapeutic agents to tumor cells in vivo, one must \n\novercome the following challengers: (i) drug resistance at the tumor level due to \n\nphysiological barriers (noncellular based mechanisms), (ii) drug resistance at the \n\ncellular level (cellular mechanisms), and (iii) distribution, biotransformation, and \n\nclearance of anticancer drugs in the body (Brigger et al., 2002).    \n\nNanovesicular drug delivery systems varying in size from 20 to 500 nm \n\nencompasses mainly unilamellar liposomes and nanocapsules (Fessi et al., 1989). \n\nNanocapsules are an attractive choice because of their oil-based central cavities, which \n\nallow a high encapsulation level for lipophilic substances such as atovaquone \n\n(Cauchetier et al., 2003). The two main factors that have limited the pratical \n\napplications of liposome tecnology are the sensitivity of phospholipid membranes to \n\nenvironmental degradation, and rapid drug leakage across the phospholipidic bilayer \n\n(Grit et al., 1989). Furthermore, many liposomes have presented a low encapsulation \n\nefficiency, a poor storage stability, and a rapid leakage of water-soluble drugs in the \n\nblood (Soppimath et al., 2001). \n\nMicroemulsions have been proposed as potential drug carrier systems for oral, \n\ntopical and parenteral administration. They offer the advantage of spontaneous \n\nformation, thermodynamic stability (Tenjarla, 1999). Moreover, further advantages of \n\no/w microemulsions as a drug delivery system include improvement of drug \n\nsolubilization and bioavailability, potential for parenteral use, easy manufacturing and \n\nscale-up, and production on large industrial scale without high-energy homogenization \n\n(Park &amp; Kim, 1999). \n\n \n\n  \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\nLichens are symbionts of fungi and algae. They commonly produce a large \n\nnumber of organic compounds, which can easily be isolated from their tissues (Bose and \n\nBanerjee, 1976). Lichenic metabolites exhibit many pharmacological properties such as \n\nantimicrobial (Bustinza, 1951; Pereira, 1991), cytostatic (Ravinskaya and Vainhstein, \n\n1975; Lawrey, 1977), antitumor (Fukuoka et al., 1968) and other activities (Appa-Rao \n\nand Prabhakar, 1987).  \n\nThe fumarprotocetraric acid, a ?-orcinol depsidone, is an aromatic aldehyde that \n\ncontains an ester side chain with a vinylic unsaturated carboxylic acid (Edwards et al., \n\n2003). The biosynthesis of the fumarprotocetraric acid has normally been confirmed by \n\nusing alginate-immobilized cells of Cladonia verticillaris (Fontaniella et al., 2000).  \n\nThe protolichesterinic acid, an ?-methylene-?-lactone, and the \n\nfumarprotocetraric acid, a ?-orcinol depsidone, are considered the major biologically \n\nactive secondary metabolites in the lichen Cetraria islandica (L.)Ach., also known as \n\nIceland moss. Its antibacterial activity has been attributed to protolichesterinic acid as \n\nwell as fumarprotocetraric acid. Lichens have long been used for medicinal purposes \n\nthroughout the ages and some, such as Cetraria islandica (Iceland moss), Lobaria \n\npulmonaria e Cladonia species were widely reputed to be effective in the treatment of \n\npulmonary tuberculosis (Vartia, 1973).  \n\nThe present work is concerned with the preparation of injectable nanocapsules of \n\npoly (lactic-co-glycolic acid) (PLGA) prepared with and without o/w microemulsion as \n\noily internal phase. Fumarprotocetraric acid was encapsulated in both  colloidal carriers \n\nin order to compare the antitumor activity of such systems. Furthermore, \n\nphysicochemical properties, cytotoxicity, and toxicity of these preparations were \n\ninvestigated. \n\n \n\n2. Materials and Methods \n\n2.1. Materials \n\nPoly (D,L-lactic-acid-co-glycolic acid) polymer (PLGA) 50:50 was purchased \n\nfrom Birmingham Polymers (USA); soya phosphatidylcholine (Epikuron 200) was \n\nobtained from Lucas Meyer (Germany); poloxamer (Synperonic F-68 ?) was generously \n\nsupplied by ICI (England); analytical grade solvents, monobasic potassium phosphate, \n\nsodium hydroxide and all other reagents with analytical grade were purchased from \n\nMerck (Darmstadt, Germany); HPLC grade acetonitrile was obtained from SIGMA-\n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nAldrich (USA). Fumarprotocetraric acid (FPA) was extracted from Cladonia \n\nverticillaris (Paraiba, Brazil), and characterized at the Chemistry Laboratory of the \n\nFederal University of Mato Grosso do Sul (UFMS), Brazil. Human lung cancer (NCI-H \n\n292) and larynx epidermoid carcinoma (HEp-2) cell lines were obtained from the \n\n'Animal Cell Catalogue', Rio de Janeiro Cell Bank, Brazil. \n\n \n\n2.2. Methods \n\n2.2.1. Formulation of microemulsions \n\nThe microemulsions were composed of Epikuron 200? as surfactant (S), \n\nCremophor? RH 40 as cosurfactant (CS), Captex? 200 as oily phase (O), and pH 7.4 \n\nphosphate buffer, as aqueous phase (A). The Epikuron 200, Cremophor? RH 40 and \n\nCaptex were mixed, and then, the aqueous phase was poured into under \n\nshaking with an Ultra Turrax apparatus (22,000 rpm for 5 min). The air incorporated to \n\nthe system was removed by ultra-sound (ultra-sound cleaner, 5 min) and the system was \n\nrefrigerated for 48 h at 4\u00b0C. Following another homogenizing cycle was carried out \n\nusing the same previous conditions (Ultra-Turrax). Finally, the system was filtrated by \n\n0.8 mm STAR membrane (Damasceno, 2004). \n\n \n\n2.2.2. Formulation of fumarprotocetraric acid loaded-nanocapsules \n\n \n\nTwo different nanocapsule formulations containing fumarprotocetraric acid \n\n(FPA) were prepared using the copolymer of lactic and glycolic acids (PLGA 50/50). \n\nThe first one consisted in using soybean oil as oily phase, whereas the other one was \n\nprepared with a mixture of soybean oil and an oil-in-water microemulsion as the oily \n\nphase.  \n\nNanocapsules formulations were manufactured according to the interfacial \n\ndeposition of a pre-formed copolymer method (Fessi et al., 1989). Briefly, the organic \n\nphase was prepared as follows. The polymer,  the phospholipid and the soybean oil were \n\neach separately dissolved in 27 ml of acetone. The fumarprotocetraric acid was \n\nsolubilized either in the soybean oil or in an oil-in-water microemulsion previously \n\nprepared (Damasceno, 2004). Acetonic phospholipid solution was obtained by \n\nincreasing the temperature to 40\u00b0C. After dissolution, both organic solutions were \n\nmixed and maintained at 40\u00b0C under magnetic stirring at 150 rpm. The aqueous phase \n\nwas consisted of poloxamer in 50 mL of a phosphate buffer solution at pH 7.4 at 0.2 M.   \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\nFinally, the organic solution was poured into the aqueous phase under magnetic \n\nstirring at 150 rpm. The acetone, which rapidly diffused towards the aqueous phase, was \n\nthen removed under reduced pressure at 40\u00b0C. The colloidal suspension was \n\nconcentrated to a 10 mL final volume by removing water under the same conditions. \n\nTwo formulations containing FPA were obtained: FPA-loaded nanocapsules (FPA-NC) \n\nand FPA-loaded nanocapsules with microemulsion (FPA-NC/ME). Unloaded similar \n\nformulations termed NC and NC-ME were also prepared as control. Formulation \n\nparameters such as the nature and the volume of the organic and aqueous phase, the \n\nnature and the concentration of surfactants and polymer have relevant implications on \n\nthe particle size distributions (Jullienne et al., 1992).  \n\n \n\n2.2.3. Physicochemical characterization and stability assesment of FPA-loaded \n\nnanocapsules \n\n \n\nThe physicochemical analysis of FPA-NC and FPA-NC/ME was carried out \n\nimmediately after preparation. Parameters such as the macroscopic aspect, pH changes, \n\nfumarprotocetraric acid content and encapsulation ratio were analyzed. All formulations \n\nwere visually observed in order to determine the homogeneity and possible change in \n\nappearance. Color, viscosity, material deposition, aggregate formation, creaming, \n\nflocculation or eventual phase separation were evaluated. The pH changes were \n\nmonitored by means of a digital pH-meter with a glass electrode.  \n\nFormulated nanocapsules were submitted to both accelerated and long-term \n\nstability testing aiming to state the formulation durability. The nanocapsule \n\nformulations were subjected to centrifugation (6,000 rpm for 1 h), mechanical stress \n\n(150 strokes/min at 37\u00b0C during 48 h) and freeze-thawing cycles (16 h at -18\u00baC \u00b1 1\u00b0C, \n\nand 8 h at 25\u00b0C \u00b1 1\u00b0C) (Jullienne et al., 1992). Long-term stability of nanocapsule \n\nsuspensions stored at 4 \u00b1 1\u00b0C was examined. Physicochemical properties of \n\npreparations were evaluated at 7, 15, 30, 45 and 60 days or until unstability signs. \n\n \n\n2.2.4. Assay of the fumarprotocetraric acid  \n\n \n\nThe fumarprotocetraric acid was assayed by high-performance liquid \n\nchromatography (Waters chromatograph system, USA). The FPA loaded into \n\nnanocapsules was extracted with 200 mL of dimethylssulfoxide (DMSO) under \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nultrasonic agitation for 5 minutes and completed to 10 mL with mobile phase \n\nacetonitrile/water (9:1). The FPA quantification was performed according to an isocratic \n\nmethod. The chromatographic run was performed using a Bondapack C18 column (10 \n\nmm particle size, 125 \u00c5, 300 mm \u00d7 3.9 mm I.D., Waters, USA) and a mobile phase \n\nconsisted of acetonitrile/water (9:1) at a flow-rate of 1 mL/min. The fumarprotocetraric \n\nacid peak was detected at a wavelength of 254 nm, with a retention time of about 1.8 \n\nmin. The calibration curve was prepared with solutions of FPA with DMSO ranging in \n\nconcentration from 2 to 10 mg/mL. The total sample volume injected into HPLC system \n\nwas 20 mL. \n\n \n\n2.2.5. Fumarprotocetraric acid encapsulation efficiency \n\n  \n\nThe encapsulation ratio of FPA into nanocapsules was determined after \n\nultrafiltration performed through ultracentrifugation  using ultrafree\u00d2 units (Millipore, \n\nUSA) for 1 h. The FPA concentration in the supernatant was determined  by HPLC as \n\nabove described. The FPA encapsulation ratio was calculated on the basis of the total \n\nFPA content into the nanocapsule formulation. \n\n \n\n2.2.6.  In vitro release profile of FPA loaded-nanocapsules \n\n  \n\nThe in vitro release profile of FPA from nanocapsules was determined according \n\nto Santos-Magalh\u00e3es et al., (1995). An aliquot of 5 mL of the fumarprotocetaric acid \n\nloaded-colloidal suspensions were directly placed into a dialysis bag (cellulose \n\nmembrane, cut off 12, 000, Sigma-Aldrich-D9652). The sample introduced in an \n\ndialysis bag was then placed into 250 mL of a solution (phosphate buffer, pH 7.4). The \n\nsystem was thermostated at 37\u00b0C \u00b1 1\u00b0C and maintained under magnetic stirring at 140 \n\nrpm. At given time intervals (0, 5, 10, 15, 30, 45, 60, 120, 240, 360 minutes and 24, 48, \n\n72 h), 2 mL aliquots of the dissolution medium was withdrawn and the FPA content \n\nwas measured by the HPLC assayed as above described. The  FPA released amount was \n\ncalculated in relation to the initial content of FPA into nanocapsules. Assays were \n\nperformed in triplicates and results were expressed in percentage of the mean values and \n\ntheir deviation. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n2.2.7. Cytotoxicity of FPA loaded-nanocapsules  \n\n \n\n The cytotoxic effect of free and encapsulated fumarprotocetraric acid was \n\nevaluated on human lung cancer cell (NCI-H 292) and larynx epidermoid carcinoma \n\ncell line (HEp-2). The cytotoxicity was evaluated by the colorimetric technique using 3-\n\n(4,5-dimethyltiazole-2)-2,5-diphenyltetrazolium bromide (MTT) (Mosmann, 1983 \n\nmodified by Alley et al., 1988). Cell suspensions were diluted to 105.cells.mL-1  and \n\naliquots of 220 \u00b5L of such a suspension were seeded on 96 well plates. After 24 hours, \n\nsamples of free and encapsulated FPA were placed in contact with NCI-H 292 and HEp-\n\n2 cells at different concentration ranging from 6.25 \u00b5g.mL-1 to 50 \u00b5g.mL-1. After 72 h \n\nincubation of cells, a solution of MTT (25 \u00b5L/well) was added and plates were \n\nincubated for 2 hours. The supernatant was removed and DMSO (100 \u00b5L/well) was \n\nadded to dissolve the formazan crystals. The reading of plates was carried out at 590 \n\nnm. The maintenance of cells and all experiments were carried out at 37\u00b0C under a 5% \n\nCO2 atmosphere. DMSO (2%) and unloaded nanocapsules were used at the same \n\nsample concentrations as controls. Each dosage group was assessed in quadruplicate. \n\nResults are expressed as the mean values of viable cells and their respective deviation. \n\n \n\n2.2.8. Toxicity of FPA- loaded nanocapsules  \n\n \n\nThe toxicity of FPA was assessed in Swiss albino mice, which were randomly \n\ndivided in four groups with six animals each one. Animals received daily intraperitoneal \n\ninjections of free, unloaded-nanocapsule and encapsulated fumarprotocetraric acid  \n\n(FPA, NC and FPA-NC/ME) at a dose of 11 mg/kg body weight for 8 weeks. The \n\ncontrol group was treated with buffered phosphate saline (pH 7.4). After treatment, \n\nanimals were sacrificed and their organs (liver, kidneys, and spleen) were submitted to \n\nhistopathological analyses. Sample tissues were preserved in a 10% buffered-formaline \n\nsolution until paraffin inclusions. Slices of sample tissues (4 \u00b5m) were prepared, and a \n\nstaining with haematoxyline and eosine was developed before examination by optical \n\nmicroscopy (Olympus BH-2, Japan). \n\n \n\n2.2.9. Antitumor activity of FPA loaded-nanocapsules   \n\n \n\nThe antitumor activity of FPA loaded-nanocapsules was evaluated in mice \n\nagainst Sarcoma 180. Tumor ascytic cells (5.106 cells.mL-1 suspension) were \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nsubcutaneously inoculated into male Swiss mice (34-41 g body weight, 45-60 days old). \n\nFour groups of six animals were randomly established as control and treated groups. \n\nChemotherapy started after 24 h of tumor implantation by intraperitoneal injections of  \n\nfree FPA or FPA loaded-nanocapsules (FPA-NC) at a dose of 15 mg.kg \u20131 per day for  7 \n\ndays. The control groups were treated with buffered phosphate saline (pH 7.4) or \n\nunloaded nanocapsules. After a week treatment, animals were sacrificed, tumor and \n\norgans (liver, spleen and kidneys) were removed. Tumor weights were measured and \n\ntumor inhibition was then calculated for treated animal groups in relation to the \n\nuntreated control group. Animal organs were submitted to histopathological analyses as \n\nabove described. Animal experiments were performed according to the National Cancer \n\nInstitute (NCI) (Geran et al., 1972) with the approval of the Ethic Committee for \n\nAnimal Experimental Assays of the Federal University of Pernambuco, Brazil. \n\n \n\n3. Results and discussions \n\n \n\n3.1. Preparation of fumarprotocetraric acid-loaded nanocapsules (FPA-NC) \n\n \n\nInitially, an attempt to optimize the amount of FPA incorporated in PLGA-\n\nnanocapules were performed to guide the choice of a stable formulation. The \n\nconcentration of constituents and parameters of formulations were varied (table 1). \n\nSeveral FPA-NC and FPA-NC/ME formulations were developed and evaluated \n\naccording to their initial  physicochemical characteristics and their long-term stability. \n\nThe FPA showed limited solubility in different solvents including acetone. In order to \n\nsolve this solubility issue, FPA was solubilized in an oil-in-water microemulsion \n\npreviously prepared.  Therefore FPA (5 mg) was incorporated in the o/w microemulsion \n\n(1.5 mL) and then introduced in the soybean oily phase. Furthermore, acetone (7 mL) \n\nwas added to the oily phase to provide a better drug solubilization. The influence of the \n\ntype and concentration of the oil was also analyzed. Concerning the oil nature, it was \n\nverified that soybean oil allowed more stable nanocapsules than sunflower oil. The \n\ninfluence of the concentration of PLGA (50/50) on the stability of nanocapsules was \n\nevaluated varying from 0.270 to 0.150 g. An amount of 150 mg of PLGA (50/50) was \n\nconsidered enough to obtain stable nanocapsules with a better physicochemical aspect \n\nafter submission to accelerated testing (centrifugation, mechanical stress and freeze-\n\nthawing cycles). A 1:1 hydrophilic-hydrophobic surfactant ratio was required to \n\nmaintain the equilibrium of this system. \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n________________________________________Simonetti, A.C._______________  \n \n\nTable 1. The nature and concentration of constituents in nanocapsule formulations\n\nConstituents Formulations\n\nNC1            NC2       NC3             NC4             NC5              NC6             NC7             NC8             NC9             NC10         \n\nPLGA (50:50mg)\n\nEpikuron 200 (mg)\n\nPoloxamer (mg)\n\nSoybean Oil (mg)\n\nMicroemulsion (ml)\n\n*FPA (mg)\n\nAcetone (ml)\n\nDMSO (ml)\n\nPhosphate buffer solution \n(pH 7.4 at 0.2M)\n\nFinal Volume\n\n*FPA - Fumar Protocetraric Acid\n\n270              200         250              150              150               150               200               200              150              150             \n\n253              200         200              150              150               150               200               200              200              220\n\n250              200         200              150              150               150               200               200              200              220\n\n270              200         250              150               150               150               200               200              150              150\n\n  -                   -              -                  -                     -                  -                     -                    -                  -                  -\n\n  80                10           10                15                 10                 20                 10                 10                10                10\n\n  28                26           27                26                 28                 28                 22                 26                40                30\n\n   -                 0.2          0.1               0.2                0.2                0.2                0.8                0.2                 -                 -\n\n  50                50           50                50                 50                 50                 50                 50                50                50\n\n  10                10           10                10                 10                 10                 10                 10                10                10\n\nConstituents Formulations\n\n   NC11          NC12     NC13           NC14           NC15            NC16           NC17           NC18           NC19         NC20            \n\nPLGA (50:50mg)\n\nEpikuron 200 (mg)\n\nPoloxamer (mg)\n\nSoybean Oil (mg)\n\nMicroemulsion (ml)\n\n*FPA (mg)\n\nAcetone (ml)\n\nDMSO (ml)\n\nPhosphate buffer solution \n(pH 7.4 at 0.2M)\n\nFinal Volume\n\n150              150         140              130               120               120               120               120              110              110            \n\n200              170         160              160               160               150               150               130              120              120\n\n200              170         160              160               160               150               150               130              120              120\n\n120              120         100              100               100               110               100               100              100              100\n\n  -                  -              -                   -                    -                    -                   -                    -                   -                  -\n\n  10                10           10                15                 10                 10                 10                 10                  5                  5\n\n  38                30           30                26                 30                 30                 28                 33                28                30\n\n   -                   -              -                   -                   -                    -                   -                  0.2               0.1                  -\n\n  50                50           50                50                 50                 50                 50                 50                50                50\n\n  10                10           10                10                 10                 10                 30                 10                10                10\n\nConstituents Formulations\n\n   NC21          NC22     NC23           NC24           NC25            NC26           NC27                      NC29         NC30            NC28\n\nPLGA (50:50mg)\n\nEpikuron 200 (mg)\n\nPoloxamer (mg)\n\nSoybean Oil (mg)\n\nMicroemulsion (ml)\n\n*FPA (mg)\n\nAcetone (ml)\n\nDMSO (ml)\n\nPhosphate buffer solution \n(pH 7.4 at 0.2M)\n\nFinal Volume\n\n125              150         125              125               120               130               150               150              150              130            \n\n100              150         150              100               130               120               125               125              120              125\n\n100              150         150              100               130               120               125               125              120              125\n\n100              100         100              100               100               100               100               100              100              100\n\n  -                  -              -                   -                    -                    -                   -                   1.5                -                   -\n\n  -                  -              -                   -                    -                    -                   -                      5                 6                   7 \n\n  25                25           25                26                 25                 25                 28                 27                30                30\n\n   -                   -              -                   -                   -                    -                   -                    -                  -                  -\n\n  50                50           50                50                 50                 50                 50                 50                50                50\n\n  10                10           10                10                 10                 10                 10                 10                10                10\n\n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n3.2. Stability assessment of fumarprotocetraric acid-loaded nanocapsules \n\n \n\nNanocapsules suspension presented an initial macroscopic aspect of a colloidal \n\nfluid with bluish hue reflect. This property is a preliminary evidence for the formation \n\nof nanocapsules.  \n\nNanocapsule suspensions prepared with and without o/w microemulsion were \n\nsubmitted to mechanical resistance testing. Only the preparation with o/w \n\nmicroemulsion maintained stability after mechanical agitation and centrifugation of \n\nnanocapsules. Both nanocapsule suspensions hold stability even after the seventh \n\nfreeze-thaw cycle. The stability of both nanocapsule formulations was maintained for \n\ntwo months when stored at 4\u00b11\u00b0C. A slight decrease in pH values was observed over a \n\nperiod of 60 days for the nanocapsules. The pH varied from 7.37 to 6.65 and from 7.43 \n\nto 6.88 for FPA-NC and FPA-NC/ME formulations, respectively (Fig. 1).  \n\nThe encapsulation efficiency of the fumarprotocetraric acid into PLGA-\n\nnanocapsules in different carriers was 49.5% (FPA-NC) and 86.2% (FPA-NC/ME) \n\nrespectively. \n\n \n\n \n\n0 10 20 30 40 50 60\n\n6.6\n\n6.7\n\n6.8\n\n6.9\n\n7.0\n\n7.1\n\n7.2\n\n7.3\n\n7.4\n\n7.5  FPA-NC\n FPA-NC/ME\n\npH\n\nTime (days)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 1. The pH evolution for nanocapsule formulations: ( ) FPA-NC, and ( ) FPA-NC/ME \n\nstored at 4 \u00b11\u00b0C. \n\n \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n3.3. In vitro release kinetic of FPA-loaded nanocapules \n\n \n\nThe kinetic profile of FPA from nanocapsule-microemulsion formulation \n\npresented a gradual augmentation on the drug release, achieveing 40.8% at 4 hours (Fig. \n\n2). Considering that the FPA encapsulation ratio of this system was 86.2%, less than \n\n50% of the encapsulated drug was released during 4 h, when a bulk saturation was \n\nobserved.  \n\n \n\n0 1 2 3 4\n0\n\n20\n\n40\n\nFP\nA\n\n r\nel\n\nea\nse\n\nd \n(%\n\n)\n\nTime (hours)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 2. In vitro kinetic profile of FPA-loaded nanocapsules prepared with o/w microemulsion \n\n(FPA-NC/ME). \n\n \n\n3.4. Cytotoxicity activity of FPA loaded-nanocapsules \n\n \n\nThe cytotoxity of the fumarprotocetraric acid on NCI-H 292 and HEp-2 cells \n\nafter 72 h incubation at different concentrations is shown in figure 4. The viability of \n\nNCI-H 292 cells treated with FPA, NC and FPA-loaded nanocapsules was observed \n\neven at 50 \u00b5g.mL-1 (Fig. 3a). In constrast, the cell treatments with o/w microemulsion \n\n(ME) or FPA-ME promoted a high cytotoxicity at 6.25 \u00b5g.mL-1 (25% cell viability). \n\nNevertheless, treatments with FPA-loaded nanocapsules-microemulsion system \n\npromoted a reduction on the cytotoxic effect allowing the determination of the IC50 \n\n(12.5 \u00b5g.mL-1). Concerning HEp-2 cells (Fig. 3b), their viability was preserved after \n\ntreatment with FPA, NC or FPA-NC even at 50 \u00b5g.mL-1. The treatment with FPA o/w \n\nmicroemulsion (ME) and FPA-ME promoted a similar cytotoxic effect (~35% cell \n\nviability) at 6.25 \u00b5g.mL-1. Results showed that FPA have no cytotoxic effects on NCI-H  \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n292 or HEp-2 cells, and FPA-loaded nanocapsules have no cytotoxic effect on NCI-H \n\n292 cells. In contrast, the o/w microemulsion exhibited a high cytotoxicity on both cells. \n\n \n\n0 10 20 30 40 50\n0\n\n20\n\n40\n\n60\n\n80\n\n100\n\n FPA\n ME\n FPA/ME\n NC\n FPA-NC\n FPA-NC/ME\n\nC\nel\n\nl v\nia\n\nbi\nlit\n\ny \n(%\n\n)\n\nConcentration (\u00b5g/mL)\n\n0 10 20 30 40 50\n0\n\n20\n\n40\n\n60\n\n80\n\n100\n\n FPA\n ME\n FPA/ME\n NC\n FPA-NC\n FPA-NC/ME\n\nC\nel\n\nl v\nia\n\nbi\nlit\n\ny \n(%\n\n)\n\nConcentration (\u00b5g/mL)\n\n \n \n\n \nFigure 3. The cytotoxic effect of the treatment with FPA-loaded nanocapsules with or without \n\noil-in-water microemulsion on (A) NCI-H 292 and (B) HEp-2 cells. \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n________________________________________Simonetti, A.C._______________  \n \n\n3.5. Toxicity of FPA-loaded nanocapsules \n \n\nNo behavioral alterations were observed in animals during the toxicity assay. No \n\nstatistically significant difference in body weight was detected for animals treated with \n\nfree and encapsulated FPA in relation to the control group. Histopathological analysis of \n\nspleen, liver and kydneys of animals treated with free FPA and FPA-loaded \n\nnanocapsules prepared with microemulsions are illustrated in figure 4. No alterations on \n\nanimal organs were revealed after treatment with FPA suspension (Fig. 4.Ia/b/c). After \n\ntreatment with unloaded and FPA-loaded nanocapsules-microemulsion, no significant \n\nalteration was detected in animal spleen (Fig. 4.IIa), which preserved their primary \n\nfoliculus. However the treatment with FPA encapsulated in NC/ME promoted  \n\npronounced injuries in liver  (Fig. 4.IIb) and kidneys (Fig. 4IIc) of animals. Cellular and \n\nrenal tubules necroses were detected in kidneys with an accentuated \n\nmesangioproliferated glomerulonephrites. Furthermore intense areas of necroses in \n\nhepatocytes were observed.  \n\n \n\nI.a\n\nI.b\n\nI.c\n\nII.a\n\nII.b\n\nII.c\n\n \n\n \n \n \n \n \n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 4. Histopathological aspect of animal organs after treatments with with free FPA \n\n(I) and FPA-loaded nanocapsules with o/w microemulsion (II): (a) spleen, (b) liver and \n\n(c) kidneys. The magnificence was 20\u00d7 (  arrays denote area of necrosis). \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\n3.7. Antitumor activity of FPA loaded-nanocapsules on Sarcoma\u2013180 tumor \n\n \n\nThe antitumor activity promoted by  free FPA, unloaded-nanocapsules and FPA-\n\nloaded nanocapsules were evaluated on Sarcoma 180-bearing mice Fig. 5 and Fig.6, \n\nrespectively. Fumarprotocetraric acid-loaded nanocapsules promoted 61.4% of tumor \n\ninhibition when compared with free FPA 58.9 % in relation to the control group. \n\nFurthermore, unloaded nanocapsules exhibited a tumor inhibition of 6.0%.  \n\n \n\nControl NC FPA FPA-NC\n0.0\n\n0.4\n\n0.8\n\n1.2\n\n1.6\n\n2.0\n\nTu\nm\n\nor\n w\n\nei\ngh\n\nt (\ng)\n\nTreatment\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 5. Evaluation of tumor weight after treatment with FPA, unloaded-nanocapsules \n\nand  FPA-loaded nanocapsules (FPA-NC), without o/w microemulsion. \n\nNC FPA FPA-NC\n0\n\n10\n\n20\n\n30\n\n40\n\n50\n\n60\n\n70\n\n80\n\nTu\nm\n\nor\n in\n\nhi\nbi\n\ntio\nn \n\n(%\n)\n\nTreatment\n\n \n\nFigure 6. Evaluation of the antitumor activity of FPA-loaded nanocapsules against \n\nSarcoma-180: free FPA and FPA-loaded nanocapsules (FPA-NC), without o/w \n\nmicroemulsion.  \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n________________________________________Simonetti, A.C._______________  \n \n\n \n\n3.7.1. Histopathological analysis  \n\n \n\nNo histological alterations were observed in organs of animals treated with free \n\n(Fig. 7.I) and FPA-loaded nanocapsules (Fig. 7.II). No morphological alterations were \n\nobserved in spleen, liver and kidneys of the animals treated with free FPA and FPA-\n\nloaded nanocapsules, differently of showing extensive areas of necrosis and  \n\nangioproliferated glomerulonephrites of groups treated with oil-in-water microemulsion. \n\n \n\n  \n\nI.a\n\n.b\n\nI.c\n\nII.a\n\nII.b\n\nII.c\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nI \n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigure 7. Histopathological aspect of animal organs after treatments with with free FPA \n\n(I) and FPA-loaded nanocapsules without o/w microemulsion (II): (a) spleen, (b) liver \n\nand (c) kidneys. The magnificence was 50\u00d7 . \n\n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n4. Conclusions \n\n \n\nResults showed that encapsulation of a poorly water soluble drugs, \n\nfumarprotocetraric acid, into PLGA-nanocapsules can be a potential alternative to allow \n\nin a diversity of therapeutical applications. The nanoencapsulation with oil-in-water \n\nmicroemulsion can therefore be considered as a potential alternative to improve \n\nsolubilization of lichens metabolites, such as fumarprotocetraric acid. However o/w \n\nmicroemulsions prepared with Cremophor? exhibited in vitro and in vivo toxicity.  \n\n \n \nAcknowledgements \n\n \nThis work received finantial support from the Brazilian National Council for \n\nScientific and Technological Development (CNPq), and a grant from the Brazilian \n\nProgramm on Nanobiotechnology (CNPq/MCT-Nanobiotec). \n\n \n\nReferences \n\n \n\nALLEY, M. C., SCUDIERO D. A., MONKS A., HURSEY M. L., CZERWINSKI, M. J., FINE, \n\nD. L., ABBOTT, B.J., MAYO, J.G., SHOEMAKER, R.H., BODY, M. R., 1988. Feasibility og \n\ndrug screening with panels of human tumour cell lines using a microculture tetrazolium assay. \n\nCancer Res., 48, 589-601.  \n\n \n\nAPPA-RAO, A. V. N. AND PRABHAKAR, M. C., 1987. Pharmacological actions of \n\nleprapinic acid: a lichen metabolite. Fitoterapia, 58 (4), 221-228. \n\n \n\nBOSE, L. AND BANERJEE, N. C., 1976. Studies on antibiotics from indian lichens part I. \n\nisolation of antibiotic compounds from Parmelia tinctorum. Bull. Botan. Soc. Bengal., 30, 125-\n\n127.  \n\n \n\nBRIGGER, I., DUBERNET, C. COUVREUR, P., 2002. Nanoparticles in cancer therapy and \n\ndiagnosis. Adv. Drug Del. Rev., 54, 631-651. \n\n \n\nBUSTINZA, F., 1951. Anticacterial substances from lichens. Endeavour, 10 (38), 95-99. \n\n \n\nCAUCHETIER, E., DENIAU, M., FESSI, H., ASTIER, A., PAUL, M., 2003. Atovaquone-\n\nloaded nanocapsules: influence of the nature of the polymer in vitro characteristics. Int. J.  \n\nPharm., 250, 273-281.  \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\nDAMASCENO, B. P. G. L., 2004. Estudo do comportamento f\u00edsico-qu\u00edmico e \n\nfarmacotoxicol\u00f3gico da anfotericina B em microemuls\u00f5es do tipo O/A. Tese (Mestrado em \n\nCi\u00eancias Farmac\u00eauticas), Universidade Federal do Rio Grande do Norte-UFRN, Brasil. \n\n \n\nEDWARDS, H. G. M., NEWTON, E. M., WYNN-WILLIAMS, D., 2003. Molecular structural \n\nstudies of lichens substances II: atranorin, gyrophoric acid, fumarprotocetraric acid, rhizocarpic \n\nacid, calycin, pulvinic dilactone and usnic acid. J. Mol. Struct., 1-11. \n\n \n\nFESSI, H.; PUISIEUX, F., DEVISSAGUET, J. P., AMMOURY, N. E., BENITA, S. N., 1989. \n\nNanocapsules formation by interfacial polymer deposition following solvent displacement. Int. \n\nJ. Pharma., 55, 1-4. \n\n \n\nFUKUOKA, F., NAKANISHI, M., SHIBATA, S., NISHIKAWA, Y., TAKEDA, TANAKA, \n\nM., 1968. Polysaccaharides in lichens and fungi II. Antitumor activities on sarcoma-180 of the \n\npolysaccaharide preparations from G. esculenta, C. Islandica, and some other lichens. Gann,  \n\n59, 421-432. \n\n \n\nFONTANIELLA, B., LEGAZ, M. E., PEREIRA, E. C., SEBASTIAN, B. VICENTE, C., 2000. \n\nRequirements to produce fumarprotocetraric acid using alginate-immobilized cells of Cladonia \n\nverticillaris. Biotechnol. Letters, 22 (10), 813-817. \n\n \n\nGAUR, U., SAHOO, S. K., DE, T. K., GHOSH, P. C., MAITRA, A., GHOSH, P. K., 2000. \n\nBiodistribuiton of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial \n\nsystem. Int. J. Pharma., 202, 1-10. \n\n \n\nGERAN, R. I., GREENBERG, N. H., MacDONALD, M. M., SCHUMACHER, A. M., \n\nABBOT, B. J., 1972. Protocols for screening chemical agents and natural products against \n\nanimal and other biological systems, 3a  ed. Cancer Chemother. Rep., v. 3, Part III, 2. \n\n \n\nGRIT, M., DE SMIDT, J. H., STRUIJKE., CROMMELIN, D. J. A., 1989. Hydrolysis of \n\nphosphatidylcholine in aqueous liposome dispersions. Int. J. Pharma., 50, 1-6. \n\n \n\nJULIENNE, M. C., ALONSO, M. J., GOMEZ AMONZA, J. L., BENOIT, J. P., 1992.  \n\nPreparation of poly (DL-lactide-glycolide) nanoparticles of controlled particle size distribuiton: \n\napplication of experimental designs. Drug Devel. Ind. Pharm., 18, 1063-1077. \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\nLAWREY, M., 1977. Inhibition of moss spore germination by aceton extracts of terricolous \n\nCladonia species. Bull. Torrey Bot. Club, 104 (1), 49-52. \n\n \n\nMOSMANN, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to \n\nproliferation and cytotoxicity assay. J. Immunol. Met., 65, 55-63.  \n\n \n\nPARK, K. &amp; KIM, C. Preparation and evaluation of flurbiprofen-loaded microemulsion for \n\nparenteral delivery. International Journal of Pharmaceutics, 181, 173-179, 1999. \n\n \n\nPEREIRA, E. C. G., CAMPOS-TAKAI, G, M., SILVA, N. H., VICENTE, C., LEGAZ, M. E., \n\nXAVIER-FILHO, L., 1991. Fractionation of Cladonia substellata crude extracts and detection \n\nof antimicrobial activity. Bol. Soc. Brot.., 64, 173-186. \n\n \n\nRAVINSKAYA, A. P. AND VAINSTEIN, E. A., 1975. Effect of some ecological factors on \n\nthe content of lichen substances. Ekologia, 6 (3), 82-85. \n\n \n\nSANTOS-MAGALH\u00c3ES, N. S., FESSI, H., PUISIEUX, F., BENITA, S. SEILLER, M., 1995. \n\nAn in vitro release kinetic examination and comparative evaluation between submicron \n\nemulsion and polylactic acid nanocapsules of chlofibride. J. Microencap.,12, 2, 195-205.  \n\n \n\nSANTOS-MAGALH\u00c3ES, N. S., PONTES, A., PEREIRA, V. M. W., CAETANO, M. N. P., \n\n2000. Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules. Int. J.  \n\nPharm., 208, 71-80.  \n\n \n\nSOPPIMATH, K. S., AMINABHAVI, T. M., KULKARNI, A. R. RUDZINSKI, W. E., 2001 \n\nBiodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled \n\nRelesase, 70, 1-20. \n\n \n\nTENJARLA, S., 1999. Microemulsions: an Overview and Pharmaceutical Applications.Crit. \n\nRew.Therap. Drug Carrier Syst., 16 (5), 61-521. \n\n \n\nVARTIA, K.O. Antibiotics in lichens., 1973. In: Ahmadjian, V., Hale, M. E. (Eds.), The \n\nLichens, Academic Press, New York, pp. 547-561. \n\n \n\n \n\n \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n5. CONCLUS\u00d5ES \n \n\nForam obtidas nanoc\u00e1psulas de PLGA, contendo o \u00e1cido fumarprotocetr\u00e1rico, \n\npreparadas sem (FPA-NC) e com o sistema de microemuls\u00e3o O/A (FPA-NC/ME), \n\ncomo fase oleosa interna, e na concentra\u00e7\u00e3o de 0,5 mg/mL, com uma taxa de \n\nencapsula\u00e7\u00e3o de 49,5 e 86,2%, respectivamente. \n\n\u2022 \n\n\u2022 O perfil cin\u00e9tico de libera\u00e7\u00e3o in vitro do \u00e1cido fumarprotocetr\u00e1rico a partir de \n\nnanoc\u00e1psulas (FPA-NC/ME) demonstrou uma libera\u00e7\u00e3o m\u00e1xima de 40,8%, nas \n\nprimeiras 4 horas, demonstrando uma libera\u00e7\u00e3o gradual ao longo do tempo. \n\n\u2022 A viabilidade das c\u00e9lulas NCI-H 292 e HEp-2 tratadas com FPA, NC e FPA-NC \n\nforam observadas at\u00e9 a  concentra\u00e7\u00e3o de 50 \u00b5g.mL-1. Em contraste, o tratamento \n\nrealizado com as formula\u00e7\u00f5es ME, FPA-ME e FPA-NC/ME exibiram elevada \n\ncitotoxidade, em ambas linhagens.  \n\n\u2022 O perfil de toxicidade in vivo demonstrou que o FPA encapsulado com o sistema \n\nmicroemuls\u00e3o promoveu les\u00f5es significativas, hep\u00e1tica e renal, confirmadas atrav\u00e9s \n\nda an\u00e1lise histopatol\u00f3gica dos \u00f3rg\u00e3os.  \n\n\u2022 Evidenciou-se que formula\u00e7\u00f5es preparadas sem o sistema de microemuls\u00e3o O/A \n\npromoveram uma inibi\u00e7\u00e3o tumoral de 61,4%, quando comparado com a sua forma \n\nlivre (58,9%), frente ao Sarcoma 180.  \n\n\u2022 Altera\u00e7\u00f5es histopatol\u00f3gicas n\u00e3o foram observadas, ap\u00f3s o tratamento \n\nquimioter\u00e1pico com o FPA em ambas formas, livre e encapsulada, quando \n\ncomparadas ao grupo controle.  \n\n\u2022 A nanoencapsula\u00e7\u00e3o com o sistema de microemuls\u00e3o O/A pode ser considerada \n\numa alternativa para melhorar a solubiliza\u00e7\u00e3o de subst\u00e2ncias liqu\u00eanicas pouco \n\nsol\u00faveis em \u00e1gua, tal como o \u00e1cido fumarprotocetr\u00e1rico. Entretanto, microemuls\u00f5es \n\npreparadas com o Cremophor? promove uma consider\u00e1vel toxicidade in vitro e in \n\nvivo; \n\n\u2022 Estes resultados indicam que a nanoencapsula\u00e7\u00e3o continua sendo uma alternativa \n\npara a aplica\u00e7\u00e3o terap\u00eautica de f\u00e1rmacos com a\u00e7\u00e3o anticancer\u00edgena, tanto para a \n\nobten\u00e7\u00e3o de uma melhor efic\u00e1cia terap\u00eautica quanto para a minimiza\u00e7\u00e3o dos efeitos \n\nt\u00f3xicos. \n\n \n\n \n\n \n\n________________________________________Simonetti, A.C._______________  \n \n\n\n\nAtividade Antitumoral e Toxicidade de Nanoc\u00e1psulas... \n\n \n\nANEXOS \n \n\n \n\n \n\n________________________________________Simonetti, A.C._______________"}]}}}